

6. References

- Abbatiello, E. & Scudder, C.L. (1970) The effect of norethynodrel with mestranol treatment of pregnant mice on the isolation-induced aggression of their male offspring. *Int. J. Fertil.*, **15**, 182–189
- Abdel-Aziz, M.T. & Williams, K.I.H. (1969) Metabolism of 17α -ethynylestradiol and its 3-methyl ether by the rabbit; an *in vivo* D-homoannulation. *Steroids*, **13**, 809–820
- Adam, S.A., Sheaves, J.K., Wright, N.H., Mosser, G., Harris, R.W. & Vessey, M.P. (1981) A case-control study of the possible association between oral contraceptives and malignant melanoma. *Br. J. Cancer*, **44**, 45–50
- Adami, H.O., Bergstrom, R., Persson, I. & Sparen, P. (1990) The incidence of ovarian cancer in Sweden, 1960–1984. *Am. J. Epidemiol.*, **132**, 446–452
- Aguiar, M.L.J.B. & Tordecilla, J.M.C. (1984) Mutagenic effect of mestranol and norgestrel in *Drosophila melanogaster*. *Actual. biol.*, **13**, 43–47 (in Spanish)
- Alton, K.B., Heteyi, N.S., Shaw, C. & Patrick, J.E. (1984) Biotransformation of norgestimate in women. *Contraception*, **29**, 19–29
- Ananijevic-Pandey, J., Jarebinski, M., Kastratovic, B., Vlajinac, H., Radojkovic, Z. & Brankovic, D. (1992) Case-control study of congenital malformations. *Eur. J. Epidemiol.*, **8**, 871–874
- Anderson, T.J., Ferguson, D.J.P. & Raab, G.M. (1982) Cell turnover in the 'resting' human breast: Influence of parity, contraceptive pill, age and laterality. *Br. J. Cancer*, **46**, 376–382
- Anderson, T.J., Battersby, S., King, R.J.B., McPherson, K. & Going, J.J. (1989) Oral contraceptive use influences resting breast proliferation. *Hum. Pathol.*, **20**, 1139–1144
- Andolsek, L., Kovacic, J., Kozuh, M. & Litt, B. (1983) Influence of oral contraceptives on the incidence of premalignant and malignant lesions of the cervix. *Contraception*, **28**, 505–519

- Andrew, F.D., Williams, T.L., Gidley, J.T. & Wall, M.E. (1972) Teratogenicity of contraceptive steroids in mice (Abstract). *Teratology*, **5**, 249
- Annapurna, V.V., Mukundan, M.A., Sesikeran, B. & Bamji, M.B. (1988) Long-term effects of female sex steroids on female rat liver in an initiator-promoter model of hepatocarcinogenesis. *Indian J. Biochem. Biophys.*, **25**, 708–713
- Ansari, S.R. & Adhami, U.M. (1977) Effect of antifertility drugs (norethindrone and mestranol) on the bone marrow chromosomes of albino rat (*Rattus norvegicus*). *Indian J. Hered.*, **9**, 7–9
- Ansari, G.A.S., Walker, R.D., Smart, V.B. & Smith, L.L. (1982) Further investigations of mutagenic cholesterol preparations. *Food chem. Toxicol.*, **20**, 35–41
- Archer, D.F., Timmer, C.J. & Lammers, P. (1994) Pharmacokinetics of a triphasic oral contraceptive containing desogestrel and ethinyl estradiol. *Fertil. Steril.*, **61**, 645–651
- Armstrong, B.K., Ray, R.M. & Thomas, D.B. (1988) Endometrial cancer and combined oral contraceptives. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. *Int. J. Epidemiol.*, **17**, 263–269
- Arya, M., Gupta, S. & Dixit, V.P. (1979) Effect of cyproterone acetate on the reproductive system of the female rat. A histological review. *Acta anat. (Basel)*, **103**, 259–265
- Aten, R.F. & Eisenfeld, A.J. (1982) Estradiol is less potent than ethinyl estradiol for *in vivo* translocation of the mammalian liver estrogen receptor to the nucleus. *Endocrinology*, **111**, 1292–1298
- Augustsson, A., Stierner, U., Rosdahl, I. & Suurkula, M. (1991) Common and dysplastic naevi as risk factors for cutaneous malignant melanoma in a Swedish population. *Acta dermatol. venerol.*, **71**, 518–524
- Bain, C., Hennekens, C.H., Speizer, F.E., Rosner, B., Willett, W. & Belanger, C. (1982) Oral contraceptive use and malignant melanoma. *J. natl Cancer Inst.*, **68**, 537–539
- Ball, P., Gelbke, H.P., Haupt, O. & Knuppen, R. (1973) Metabolism of 17α -ethynyl-[4- ^{14}C]-oestradiol and [4- ^{14}C]mestranol in rat liver slices and interaction between 17α -ethynyl-2-hydroxyoestradiol and adrenalin. *Hoppe-Seyler's Z. physiol. Chem.*, **354**, 1567–1575
- Banduhn, N. & Obe, G. (1985) Mutagenicity of methyl 2-benzimidazolecarbamate, diethylstilbestrol and estradiol: Structural chromosomal aberrations, sister-chromatid exchanges, C-mitoses, polyploidies and micronuclei. *Mutat. Res.*, **156**, 199–218
- Banerjee, S.K., Banerjee, S., Li, S.A. & Li, J.J. (1994) Induction of chromosome aberrations in Syrian hamster renal cortical cells by various estrogens. *Mutat. Res.*, **311**, 191–197
- Barnes, R.B. & Lobo, R.A. (1987) Pharmacology of estrogens. In: Mishell, D.R., Jr, ed., *Meno-pause: Physiology and Pharmacology*, Chicago, IL, Year Book Medical Publishers, pp. 301–315
- Bauer, H.M., Hildesheim, A., Schiffman, M.H., Glass, A.G., Rush, B.B., Scott, D.R., Cadell, D.M., Kurman, R.J. & Manos, M.M. (1993) Determinants of genital human papillomavirus infection in low-risk women in Portland, Oregon. *Sex. transm. Dis.*, **20**, 274–278
- Baumann, A., Kulmann, H., Gorkov, V., Mahler, M. & Kuhnz, W. (1996) Radioimmunological analysis of cyproterone acetate in human serum. *Arzneimittel-Forsch./Drug Res.*, **46**, 412–418

- Becker, T.M., Wheeler, C.M., McGough, N., Stidley, C.A., Parmenter, C.A., Dorin, M.H. & Jordan, S.W. (1994) Contraceptive and reproductive risks for cervical dysplasia in southwestern Hispanic and non-Hispanic white women. *Int. J. Epidemiol.*, **23**, 913–922
- Beral, V., Ramcharan, S. & Faris, R. (1977) Malignant melanoma and oral contraceptive use among women in California. *Br. J. Cancer*, **36**, 804–809
- Beral, V., Evans, S., Shaw, H. & Milton, G. (1984) Oral contraceptive use and malignant melanoma in Australia. *Br. J. Cancer*, **50**, 681–685
- Beral, V., Hannaford, P. & Kay, C. (1988) Oral contraceptive use and malignancies of the genital tract. Results of the Royal College of General Practitioners' Oral Contraception Study. *Lancet*, **ii**, 1331–1335
- Beral, V., Hermon, C., Kay, C., Hannaford, P., Darby, S. & Reeves, G. (1999) Mortality in relation to oral contraceptive use: 25 year follow-up of women in the Royal College of General Practitioners Oral Contraception study. *Br. med. J.*, **318**, 96–100
- Bergink, E.W., van Meel, F., Turpijn, W. & van der Vies, J. (1983) Binding of progestagens to receptor proteins in MCF-7 cells. *J. Steroid Biochem.*, **19**, 1563–1570
- Bernstein, L., Pike, M.C., Krailo, M. & Henderson, B.E. (1990) Update of the Los Angeles study of oral contraceptives and breast cancer: 1981 and 1983. In: Mann, R.D., ed., *Oral Contraceptives and Breast Cancer*, Camforth, Publishing Group Limited, pp. 169–181
- Blakey, D.C. & White, I.N.H. (1985) Unscheduled DNA synthesis caused by norethindrone and related contraceptive steroids in short-term male rat hepatocyte cultures. *Carcinogenesis*, **6**, 1201–1205
- Blanzat-Reboud, S. & Russfield, A.B. (1969) Effect of parenteral steroids on induction of genital tumors in mice by 20-methylcholanthrene. *Am. J. Obstet. Gynecol.*, **103**, 96–101
- Bokkenheuser, V.D., Winter, J., Mosenthal, A.C., Mosbach, E.H., McSherry, C.K., Ayengar, N.K.N., Andrews, A.W., Lebherz, W.B., III, Pienta, R.J. & Wallenstein, S. (1983) Fecal steroid 21-dehydroxylase, a potential marker for colorectal cancer. *Am. J. Gastroenterol.*, **78**, 469–475
- Bolt, H.M. (1979) Metabolism of estrogens—natural and synthetic. *Pharmacol. Ther.*, **4**, 155–181
- Bolt, H.M. & Bolt, W.H. (1974) Pharmacokinetics of mestranol in man in relation to its oestrogenic activity. *Eur. J. clin. Pharmacol.*, **7**, 295–305
- Booth, M., Beral, V. & Smith, P. (1989) Risk factors for ovarian cancer: A case-control study. *Br. J. Cancer*, **60**, 592–598
- Booth, M., Beral, V., Maconochie, N., Carpenter, L. & Scott, C. (1992) A case-control study of benign ovarian tumours. *J. Epidemiol. Community Health*, **46**, 528–531
- Bosch, F.X., Muñoz, N., de Sanjosé, S., Izaizugaza, I., Gili, M., Viladiu, P., Tormo, M.J., Moreo, P., Ascunce, N., Gonzalez, L.C., Tafur, L., Kaldor, J.M., Guerrero, E., Aristizabal, N., Santamaria, M., de Ruiz, P.A. & Shah, K.V. (1992) Risk factors for cervical cancer in Colombia and Spain. *Int. J. Epidemiol.*, **52**, 750–758
- Bosch, F.X., Muñoz, N., de Sanjosé, S., Eluf Neto, J., Orfila, J., Walboomers, J. & Shah, K. (1995) What is relevant in cervical carcinogenesis other than HPV? In: Monsonego, J., ed., *Challenges of Modern Medicine*, Vol. 9, *Papillomavirus in Human Pathology*, Paris, Ares-Serono Symposia Publications, pp. 173–181

- Bostick, R.M., Potter, J.D., Kushi, L.H., Sellers, T.A., Steinmetz, K.A., McKenzie, D.R., Gapstur, S.M. & Folsom, A.R. (1994) Sugar, meat, and fat intake, and non-dietary risk factors for colon cancer incidence in Iowa women (United States). *Cancer Causes Control*, **5**, 38–52
- Botella, J., Paris, J. & Lahlou, B. (1987) The cellular mechanism of the antiandrogenic action of nomegestrol acetate, a new 19-nor progestagen, on the rat prostate. *Acta endocrinol.*, **115**, 544–550
- Botella, J., Duc, I., Delansorne, R., Paris, J. & Lahlou, B. (1990) Structure–activity and structure–affinity relationships of 19-nor-progesterone derivatives in rat uterus. *J. endocrinol. Invest.*, **13**, 905–910
- Botella, J., Duranti, E., Duc, I., Cognet, A.M., Delansorne, R. & Paris, J. (1994) Inhibition by nomegestrol acetate and other synthetic progestins on proliferation and progesterone receptor content of T47-D human breast cancer cells. *J. Steroid Biochem. mol. Biol.*, **50**, 41–47
- Botella, J., Duranti, E., Viader, V., Duc, I., Delansorne, R. & Paris, J. (1995) Lack of estrogenic potential of progesterone- or 19-nor-progesterone-derived progestins as opposed to testosterone or 19-nortestosterone derivatives on endometrial Ishikawa cells. *J. Steroid Biochem. mol. Biol.*, **55**, 77–84
- Bracken, M.B. (1990) Oral contraception and congenital malformations in offspring: A review and meta-analysis of the prospective studies. *Obstet. Gynecol.*, **76**, 552–557
- Breiner, M., Romalo, G. & Schweikert, H.-U. (1986) Inhibition of androgen receptor binding by natural and synthetic steroids in cultured human genital skin fibroblasts. *Klin. Wochenschr.*, **64**, 732–737
- Brent, R.L. (1989) Kudos to the Food and Drug Administration: Reversal of the package insert warning for birth defects for oral contraceptives. *Teratology*, **39**, 93–94
- Brent, R.L. (1994) Cardiovascular birth defects and prenatal exposure to female sex hormones: Importance of utilising proper epidemiological methods and teratologic principles. *Teratology*, **49**, 159–161
- Brewster, D., Jones, R.S. & Symons, A.M. (1977) Effects of neomycin on the biliary excretion and enterohepatic circulation of mestranol and 17 β -oestradiol. *Biochem. Pharmacol.*, **26**, 943–946
- Briggs, M.H. (1975) Contraceptive steroid binding to the human uterine progesterone-receptor. *Curr. med. Res. Opin.*, **3**, 95–98
- Brinkmann, A.O., Lindh, L.M., Breedveld, D.I., Mulder, E. & Van der Molen, H.J. (1983) Cyproterone acetate prevents translocation of the androgen receptor in the rat prostate. *Mol. cell. Endocrinol.*, **32**, 117–129
- Brinton, L.A., Hoover, R., Szklo, M. & Fraumeni, F.J., Jr (1982) Oral contraceptives and breast cancer. *Int. J. Epidemiol.*, **11**, 316–322
- Brinton, L.A., Huggins, G.R., Lehman, H.F., Mallin, K., Szvitz, D.A., Trapido, E., Rosenthal, J. & Hoover, R. (1986) Long-term use of oral contraceptives and risk of invasive cervical cancer. *Int. J. Cancer*, **38**, 339–344
- Brinton, L.A., Tashima, K.T., Lehman, H.F., Levine, R.S., Mallin, K., Savitz, D.A., Stolley, P.D. & Fraumeni, J.F., Jr (1987) Epidemiology of cervical cancer by cell type. *Cancer Res.*, **47**, 1706–1711

- Brinton, L.A., Reeves, W.C., Brenes, M.M., Herrero, R., De Britton, R.C., Gaitan, E., Tenorio, F., Garcia, M. & Rawls, W.E. (1990) Oral contraceptive use and risk of invasive cervical cancer. *Int. J. Epidemiol.*, **19**, 4–11
- Brinton, L.A., Daling, J.A., Liff, J.M., Schoenberg, J.B., Malone, K.E., Stanford, J.L., Coates, R.J., Gammon, M.D., Hanson, L. & Hoover, R.N. (1995) Oral contraceptives and breast cancer risk among young women. *J. natl Cancer Inst.*, **87**, 827–835
- British Medical Association (1997) *British National Formulary*, No. 34, London, Royal Pharmaceutical Society of Great Britain, pp. 345–349
- Brock, K.E., Berry, G., Brinton, L.A., Kerr, C., MacLennan, R. & Mock, P.A. (1989) Sexual reproductive and contraceptive risk factors for carcinoma in situ of the uterine cervix in Sydney. *Med. J. Austr.*, **150**, 125–130
- van der Burg, B., Kalkhoven, E., Isbrücker, L. & de Laat, S.W. (1992) Effects of progestins on the proliferation of estrogen-dependent human breast cancer cells under growth factor-defined conditions. *J. Steroid Biochem. mol. Biol.*, **42**, 457–465
- Burk, R.D., Kelly, P., Feldman, J., Bromberg, J., Vermund, S.H., Dehovitz, J.A. & Landesman, S.H. (1996) Declining prevalence of cervicovaginal human papillomavirus infection with age is independent of other risk factors. *Sex. transm. Dis.*, **23**, 333–341
- Bursch, W., Düsterberg, B. & Schulte-Hermann, R. (1986) Growth, regression and cell death in rat liver as related to tissue levels of the hepatomitogen cyproterone acetate. *Arch. Toxicol.*, **59**, 221–227
- Bursch, W., Oberhammer, F., Jirtle, R.L., Askari, M., Sedivy, R., Grasl-Kraupp, B., Purchio, A.F. & Schulte-Hermann, R. (1993) Transforming growth factor- β 1 as a signal for induction of cell death by apoptosis. *Br. J. Cancer*, **67**, 531–536
- Burton, S. & Trachtenberg, J. (1986) Effectiveness of antiandrogens in the rat. *J. Urol.*, **136**, 932–935
- Bustan, M.H., Coker, A.L., Addy, C.L., Macera, C.A., Greene, F. & Sampoerno, D. (1993) Oral contraceptive use and breast cancer in Indonesia. *Contraception*, **47**, 241–249
- Campen, D., Maronpot, R. & Lucier, G. (1990) Dose–response relationships in promotion of rat hepatocarcinogenesis by 17 β -ethinylestradiol. *J. Toxicol. environ. Health*, **29**, 257–268
- Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development (1986) Oral contraceptive use and the risk of breast cancer. *New Engl. J. Med.*, **315**, 405–411
- Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development (1987) The reduction in risk of ovarian cancer associated with oral contraceptive use. *New Engl. J. Med.*, **316**, 650–655
- Carol, W., Klinger, G., Jäger, R., Kasch, R. & Brandstädt, A. (1992) Pharmacokinetics of ethinylestradiol and levonorgestrel after administration of two oral contraceptive preparations. *Exp. clin. Endocrinol.*, **99**, 12–17
- Casagrande, J.T., Louie, E.W., Pike, M.C., Roy, S., Ross, R.K. & Henderson, B.E. (1979) Incessant ovulation and ovarian cancer. *Lancet*, **ii**, 170–173
- Catherino, W.H. & Jordan, V.C. (1995) Nomegestrol acetate, a clinically useful 19-norprogesterone derivative which lacks estrogenic activity. *J. Steroid Biochem. mol. Biol.*, **55**, 239–246

- Catherino, W.H., Jeng, M.H. & Jordan, V.C. (1993) Norgestrel and gestodene stimulate breast cancer cell growth through an oestrogen receptor mediated mechanism. *Br. J. Cancer*, **67**, 945–952
- Cavalieri, E.L., Stack, D.E., Devanesan, P.D., Todorovic, R., Dwivedy, I., Higginbotham, S., Johansson, S.L., Patil, K.D., Gross, M.L., Gooden, J.K., Ramanathan, R., Cerny, R.L. & Rogan, E.G. (1997) Molecular origin of cancer: Catechol estrogen-3,4-quinones as endogenous tumor initiators. *Proc. natl Acad. Sci. USA*, **94**, 10937–10942
- Caviezel, M., Lutz, W.K. & Minini, C. (1984) Interaction of estrone and estradiol with DNA and protein of liver and kidney in rat and hamster in vivo and in vitro. *Arch. Toxicol.*, **55**, 97–103
- Celentano, D.D., Klassen, A.C., Weisman, C.S. & Rosenshein, N.B. (1987) The role of contraceptive use in cervical cancer: The Maryland cervical cancer case–control study. *Am. J. Epidemiol.*, **126**, 592–604
- Centers for Disease Control and the National Institute of Child Health and Human Development, Cancer and Steroid Hormone Study (1987) Combination oral contraceptive use and the risk of endometrial cancer. *J. Am. med. Assoc.*, **257**, 796–800
- Centers for Disease Control Cancer and Steroid Hormone Study (1983a) Long-term oral contraceptive use and the risk of breast cancer. *J. Am. med. Assoc.*, **249**, 1591–1595
- Centers for Disease Control Cancer and Steroid Hormone Study (1983b) Oral contraceptive use and the risk of ovarian cancer. *J. Am. med. Assoc.*, **249**, 1596–1599
- Cerbón, M.A., Pasapera, A.M., Gutiérrez-Sagal, R., García, G.A. & Pérez-Palacios, G. (1990) Variable expression of the uteroglobin gene following the administration of norethisterone and its A-ring reduced metabolites. *J. Steroid Biochem.*, **36**, 1–6
- Chaouki, N., Bosch, F.X., Muñoz, N., Meijer, C.J.L.M., El Gueddari, B., El Ghazi, A., Deacon, J., Castellsagué, X. & Walboomers, J.M.M. (1998) The viral origin of cervical cancer in Rabat, Morocco. *Int. J. Cancer*, **75**, 546–554
- Chhabra, S.K., Kaur, S. & Rao, A.R. (1995) Modulatory influence of the oral contraceptive pill, Ovral, on 3-methylcholanthrene-induced carcinogenesis in the uterus of mouse. *Oncology*, **52**, 32–34
- Chilvers, C., Mant, D. & Pike, M.C. (1987) Cervical adenocarcinoma and oral contraceptives. *Br. med. J.*, **295**, 1446–1447
- Chilvers, C.E.D., Smith, S.J. & Members of the UK National Case–Control Study Group (1994) The effect of patterns of oral contraceptive use on breast cancer risk in young women. *Br. J. Cancer*, **67**, 922–923
- Chow, W.-H., McLaughlin, J.K., Mandel, J.S., Blot, W.J., Niwa, S. & Fraumeni, J.F., Jr (1995) Reproductive factors and the risk of renal cell cancer among women. *Int. J. Cancer*, **60**, 321–324
- Chute, C.G., Willett, W.C., Colditz, G.A., Stampfer, M.J., Rosner, B. & Speizer, F.E. (1991) A prospective study of reproductive history and exogenous estrogens on the risk of colorectal cancer in women. *Epidemiology*, **2**, 201–207
- Clarke, E.A., Hatcher, J., McKeown-Eyssen, G.E. & Lickrish, G.M. (1985) Cervical dysplasia: Association with sexual behavior, smoking, and oral contraceptive use? *Am. J. Obstet. Gynecol.*, **151**, 612–616

- Clavel, F., Andrieu, N., Gairard, B., Brémand, A., Piana, L., Lansac, J., Bréart, G., Rumeau-Rouquette, C., Flamant, R. & Renaud, R. (1991) Oral contraceptives and breast cancer: A French case-control study. *Int. J. Epidemiol.*, **20**, 32–38
- Clos, V., Esteve, A., Jane, F. & Salva, P. (1988) Microsomal effects of cyproterone acetate and flutamide in rat testis. *Gen. Pharmacol.*, **19**, 393–397
- Coenen, C.M.H., Thomas, C.M.G., Borm, G.F., Hollanders, J.M.G. & Rolland, R. (1996) Changes in androgens during treatment with four low-dose contraceptives. *Contraception*, **53**, 171–176
- Cozy, E., Auzan, C., Lonigro, A., Philippe, M., Menard, J. & Corvol, P. (1987) Effect of mestranol on cell proliferation and angiotensinogen production in HepG2 cells: Relation with the cell cycle and action of tamoxifen. *Endocrinology*, **120**, 133–141
- Cohen, C.J. & Deppe, G. (1977) Endometrial carcinoma and oral contraceptive agents. *Obstet. Gynecol.*, **49**, 390–392
- Coker, A.L., McCann, M.F., Hulka, B.S. & Walton, L.A. (1992) Oral contraceptive use and cervical intraepithelial neoplasia. *J. clin. Epidemiol.*, **45**, 1111–1118
- Coldham, N.G. & James, V.H. (1990) A possible mechanism for increased breast cell proliferation by progestins through increased reductive 17 β -hydroxysteroid dehydrogenase activity. *Int. J. Cancer*, **45**, 174–178
- Colditz, G.A. for the Nurses' Health Study Research Group (1994) Oral contraceptive use and mortality during 12 years of follow-up: The Nurses' Health Study. *Ann. intern. Med.*, **120**, 821–826
- Collaborative Group on Hormonal Factors in Breast Cancer (1996a) Breast cancer and hormonal contraceptives: Further results. *Contraception*, **54** (Suppl. 3), 1S–106S
- Collaborative Group on Hormonal Factors in Breast Cancer (1996b) Breast cancer and hormonal contraceptives: Collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. *Lancet*, **347**, 1713–1727
- Collaborative MILTS Project Team (1997) Oral contraceptives and liver cancer. *Contraception*, **56**, 275–284
- Colletta, A.A., Howell, F.V. & Baum, M. (1989) A novel binding site for a synthetic progestagen in breast cancer cells. *J. Steroid Biochem.*, **33**, 1055–1061
- Colletta, A.A., Wakefield, L.M., Howell, F.V., Danielpour, D., Baum, M. & Sporn, M.B. (1991) The growth inhibition of human breast cancer cells by a novel synthetic progestin involves the induction of transforming growth factor beta. *J. clin. Invest.*, **87**, 277–283
- Committee on Safety of Medicines (1972) *Carcinogenicity Tests of Oral Contraceptives*, London, Her Majesty's Stationery Office
- Coni, P., Simbula, G., DePrati, A.C., Menegazzi, M., Suzuki, H., Sarma, D.S.R., Ledda-Columbano, G.M. & Columbano, A. (1993) Differences in the steady-state levels of *c-fos*, *c-jun* and *c-myc* messenger RNA during mitogen-induced liver growth and compensatory regeneration. *Hepatology*, **17**, 1109–1116
- Cooke, B.A. & Vallance, D.K. (1965) Metabolism of megestrol acetate and related progesterone analogues by liver preparations *in vitro*. *Biochem. J.*, **97**, 672–677

- Cooper, J.M. & Kellie, A.E. (1968) The metabolism of megestrol acetate (17- α -acetoxy-6-methylpregna-4,6-diene-3,20-dione) in women. *Steroids*, **11**, 133–149
- Cottinet, D., Czyba, J.C., Dams, R. & Laurent, J.L. (1974) Effects of long-term administration of anti-ovulatory steroids on the fertility of female golden hamsters and their progeny. *C.R. Soc. Biol.*, **168**, 517–520 (in French)
- Cramer, D.W., Hutchison, G.B., Welch, W.R., Scully, R.E. & Knapp, R.C. (1982) Factors affecting the association of oral contraceptives and ovarian cancer. *New Engl. J. Med.*, **307**, 1047–1051
- Cuzick, J., Singer, A., De Stavola, B.L. & Chomet, J. (1990) Case-control study of risk factors for cervical intraepithelial neoplasia in young women. *Eur. J. Cancer*, **26**, 684–690
- Daling, J.R., Madeleine, M.M., McKnight, B., Carter, J.J., Wipf, G.C., Ashley, R., Schwartz, S.M., Beckmann, A.M., Hagensee, M.E., Mandelson, M.T. & Galloway, D.A. (1996) The relationship of human papillomavirus-related cervical tumors to cigarette smoking, oral contraceptive use, and prior herpes simplex virus type 2 infection. *Cancer Epidemiol. Biomarkers Prev.*, **5**, 541–548
- Darney, P.D. (1995) The androgenicity of progestins. *Am. J. Med.*, **98** (Suppl. 1A), 104S–110S
- Dayan, J., Crajer, M.C., Bertozzi, S. & Lefrancois, S. (1980) Application of the *Salmonella typhimurium* microsome test to the study of 25 drugs belonging to 5 chemical series. *Mutat. Res.*, **77**, 301–306
- Deml, E., Schwarz, L.R. & Oesterle, D. (1993) Initiation of enzyme-altered foci by the synthetic steroid cyproterone acetate in rat liver foci bioassay. *Carcinogenesis*, **14**, 1229–1231
- De Vet, H.C.W., Knipschild, P.G. & Sturmans, F. (1993) The role of sexual factors in the aetiology of cervical dysplasia. *Int. J. Epidemiol.*, **22**, 798–803
- Dhillon, V.S. & Dhillon, I.K. (1996) Genotoxicity evaluation of norethisterone acetate. *Mutat. Res.*, **367**, 1–10
- Dhillon, V.S., Singh, J.S., Singh, H. & Kler, R.S. (1994) In vitro and in vivo genotoxicity evaluation of hormonal drugs. V. Mestranol. *Mutat. Res.*, **322**, 173–183
- Di Carlo, F., Gallo, E., Conti, G. & Racca, S. (1983) Changes in the binding of oestradiol to uterine oestrogen receptors induced by some progesterone and 19-nor-testosterone derivatives. *J. Endocrinol.*, **98**, 385–389
- Doll, R. (1985) Invasive cervical cancer and combined oral contraceptives (Letter to the Editor). *Br. med. J.*, **290**, 1210
- Dragan, Y.P., Singh, J. & Pitot, H.C. (1996) Effect of the separate and combined administration of mestranol and phenobarbital on the development of altered hepatic foci expressing placental form of glutathione S-transferase in the rat. *Carcinogenesis*, **17**, 2043–2052
- Drevon, C., Piccoli, C. & Montesano, R. (1981) Mutagenicity assays of estrogenic hormones in mammalian cells. *Mutat. Res.*, **89**, 83–90
- Drill, V.A. (1966). *Oral Contraceptives*, New York, McGraw-Hill, pp. 6–7
- Duc, I., Botella, J., Bonnet, P., Fraboul, F., Delansorne, R. & Paris, J. (1995) Antiandrogenic properties of nomegestrol acetate. *Arzneimittelforschung*, **45**, 70–74
- Dugwekar, Y.G., Narula, R.K. & Laumas, K.R. (1973) Disappearance of 1α - ^3H -chlormadinone acetate from the plasma of women. *Contraception*, **7**, 27–45

- Duivenvoorden, W.C.M. & Maier, P. (1994) Nongenotoxic carcinogens shift cultured rat hepatocytes into G1 cell cycle phase: Influence of tissue oxygen tension on cells with different ploidy. *Eur. J. Cell Biol.*, **64**, 368–375
- Duivenvoorden, W.C.M., Schäfer, R., Pfeifer, A.M.A., Piquet, D. & Maier, P. (1995) Nuclear matrix condensation and *c-myc* and *c-fos* expression are specifically altered in cultured rat hepatocytes after exposure to cyproterone acetate and phenobarbital. *Biochem. biophys. Res. Comm.*, **215**, 598–605
- Dunkel, V.C., Pienta, R.J., Sivak, A. & Traul, K.A. (1981) Comparative neoplastic transformation responses of Balb/3T3 cells, Syrian hamster embryo cells, and Rauscher murine leukemia virus-infected Fischer 344 rat embryo cells to chemical carcinogens. *J. natl Cancer Inst.*, **67**, 1303–1315
- Dunkel, V.C., Zeiger, E., Brusick, D., McCoy, E., McGregor, D., Mortelmans, K., Rosenkranz, H.S. & Simmon, V.F. (1984) Reproducibility of microbial mutagenicity assays: I. Tests with *Salmonella typhimurium* and *Escherichia coli* using a standardized protocol. *Environ. Mutag.*, **6** (Suppl. 2), 1–254
- Dutkowski, R.T., Kevin, M.J. & Jenkins, E.C. (1983) The effect of oral contraceptives on sister chromatid exchange, blast transformation, mitotic index and micronuclei formation. *Exp. Cell Biol.*, **51**, 115–120
- Duval, D., Durant, S. & Homo-Delarche, F. (1983) Non-genomic effects of steroids: Interactions of steroid molecules with membrane structures and functions. *Biochim. biophys. Acta.*, **737**, 409–442
- Ebeling, K., Nischan, P. & Schindler, C. (1987) Use of oral contraceptives and risk of invasive cervical cancer in previously screened women. *Int. J. Cancer*, **39**, 427–430
- Ebeling, K., Ray, R., Nischan, P., Thomas, D.B., Kunde, D. & Stalsberg, H. (1991) Combined oral contraceptives containing chlormadinone acetate and breast cancer: Results of a case-control study. *Br. J. Cancer*, **63**, 804–808
- Edmondson, H.A., Henderson, B. & Benton, B. (1976) Liver-cell adenomas associated with use of oral contraceptives. *New Engl. J. Med.*, **294**, 470–472
- Edwards, A.M. & Lucas, C.M. (1985) Induction of γ -glutamyl transpeptidase in primary cultures of normal rat hepatocytes by liver tumor promoters and structurally related compounds. *Carcinogenesis*, **6**, 733–739
- Eibs, H.G., Spielmann, H. & Hägele, M. (1982) Teratogenic effects of cyproterone acetate and medroxyprogesterone treatment during the pre- and postimplantation period of mouse embryos.1. *Teratology*, **25**, 27–36
- Eisenfeld, A.J., Aten, R.F. & Weinberger, M.J. (1978) Oral contraceptives—possible mediation of side effects via an estrogen receptor in liver. *Biochem. Pharmacol.*, **27**, 2571–2575
- El Etreby, M.F., Habenicht, U.-F., Louton, T., Nishino, Y. & Schröder, H.G. (1987) Effect of cyproterone acetate in comparison to flutamide and megestrol acetate on the ventral prostate, seminal vesicle and adrenal glands of adult male rats. *Prostate*, **11**, 361–375
- Ellery, C., MacLennan, R., Berry, G. & Shearman, R.P. (1986) A case-control study of breast cancer in relation to the use of steroid contraceptive agents. *Med. J. Aust.*, **144**, 173–176

- Eluf-Neto, J., Booth, M., Muñoz, N., Bosch, F.X., Meijer, C.J.L.M. & Walboomers, J.M.M. (1994) Human papillomavirus and invasive cervical cancer in Brazil. *Br. J. Cancer*, **69**, 114–119
- Epstein, S.S., Arnold, E., Andrea, J., Bass, W. & Bishop, Y. (1972) Detection of chemical mutagens by the dominant lethal assay in the mouse. *Toxicol. appl. Pharmacol.*, **23**, 288–325
- Ericson, A., Källén, B. & Lindsten, J. (1983) Lack of correlation between contraceptive pills and Down's syndrome. *Acta obstet. gynecol. scand.*, **62**, 511–514
- Ewertz, M. (1992) Oral contraceptives and breast cancer risk in Denmark. *Eur. J. Cancer*, **28A**, 1176–1181
- Farley, T.M., Meirik, O., Poulter, N.R., Chang, C.L. & Marmot, M.G. (1996) Oral contraceptives and thrombotic diseases: Impact of new epidemiological studies. *Contraception*, **54**, 193–198
- Fathalla, M.F. (1971) Incessant ovulation—a factor in ovarian neoplasia? (Letter to the Editor) *Lancet*, **ii**, 163
- Fernandez, E., La Vecchia, C., D'Avanzo, B., Franceschi, S., Negri, E. & Parazzini, F. (1996) Oral contraceptives, hormone replacement therapy and the risk of colorectal cancer. *Br. J. Cancer*, **73**, 1431–1435
- Fernandez, E., La Vecchia, C., Franceschi, S., Braga, C., Talamini, R., Negri, E. & Parazzini, F. (1998) Oral contraceptive use and risk of colorectal cancer. *Epidemiology*, **9**, 295–300
- Fitzgerald, J., DeLaGlesia, F. & Goldenthal, E.I. (1982) Ten-year oral toxicity study with Norlestrin in rhesus monkey. *J. Toxicol. environ. Health*, **10**, 879–896
- Føggh, M., Corker, C.S., Hunter, W.M., McLean, H., Philip, J., Schou, G. & Skakkebaek, N.E. (1979) The effects of low doses of cyproterone acetate on some functions of the reproductive systems in normal men. *Acta endocrinol.*, **91**, 545–552
- Foote, W.D., Foote, W.C. & Foote, L.H. (1968) Influence of certain natural and synthetic steroids on genital development in guinea pigs. *Fertil. Steril.*, **19**, 606–615
- Forman, D., Doll, R. & Peto, R. (1983) Trends in mortality from carcinoma of the liver and the use of oral contraceptives. *Br. J. Cancer*, **48**, 349–354
- Forman, D., Vincent, T.J. & Doll, R. (1986) Cancer of the liver and the use of oral contraceptives. *Br. med. J.*, **292**, 1357–1361
- Forsberg, J.-G. (1991) Estrogen effects on chromosome number and sister chromatid exchanges in uterine epithelial cells and kidney cells from neonatal mice. *Teratog. Carcinog. Mutag.*, **11**, 135–146
- Forsberg, J.-G. & Jacobsohn, D. (1969) The reproductive tract of males delivered by rats given cyproterone acetate from days 7 to 21 of pregnancy. *J. Endocrinol.*, **44**, 461–462
- Fotherby, K. (1995) Levonorgestrel: Clinical pharmacokinetics. *Clin. Pharmacokin.*, **28**, 203–215
- Francavilla, A., Polimeno, L., DiLeo, A., Barone, M., Ove, P., Coetzee, M., Eagon, P., Makowka, L., Ambrosino, G., Mazzaferro, V. & Starzl, T.E. (1989) The effect of estrogen and tamoxifen on hepatocyte proliferation *in vivo* and *in vitro*. *Hepatology*, **9**, 614–620
- Franceschi, S., La Vecchia, C., Helmrich, S.P., Mangioni, C. & Tognoni, G. (1982) Risk factors for epithelial ovarian cancer in Italy. *Am. J. Epidemiol.*, **115**, 714–719
- Franceschi, S., Fassina, A., Talamini, R., Mazzolini, A., Vianello, S., Bidoli, E., Cizza, G. & La Vecchia, C. (1990) The influence of reproductive and hormonal factors on thyroid cancer in women. *Rev. Epidemiol. Santé publ.*, **38**, 27–34

- Franceschi, S., Parazzini, F., Negri, E., Booth, M., La Vecchia, C., Beral, V., Tzonou, A. & Trichopoulos, D. (1991a) Pooled analysis of 3 European case-control studies of epithelial ovarian cancer. III. Oral contraceptive use. *Int. J. Cancer*, **49**, 61–65
- Franceschi, S., Bidoli, E., Talamini, R., Barra, S. & La Vecchia, C. (1991b) Colorectal cancer in northeastern Italy: Reproductive, menstrual and female hormone-related factors. *Eur. J. Cancer*, **27**, 604–608
- Fuhrmann, U., Bengtson, C., Repenthin, G. & Schillinger, E. (1992) Stable transfection of androgen receptor and MMTV-CAT into mammalian cells: Inhibition of CAT expression by anti-androgens. *J. Steroid Biochem. mol. Biol.*, **42**, 787–793
- Fuhrmann, U., Slater, E.P. & Fritzemeier, K.-H. (1995) Characterization of the novel progestin gestodene by receptor binding studies and transactivation assays. *Contraception*, **51**, 45–52
- Furner, S.E., Davis, F.G., Nelson, R.L. & Haenszel, W. (1989) A case-control study of large bowel cancer and hormone exposure in women. *Cancer Res.*, **49**, 4936–4940
- Galanti, M.R., Hansson, L., Lund, E., Bergström, R., Grimelius, L., Stalsberg, H., Carlsen, E., Baron, J.A., Persson, I. & Ekblom, A. (1996) Reproductive history and cigarette smoking as risk factors for thyroid cancer in women: A population-based case-control study. *Cancer Epidemiol. Biomarkers Prev.*, **5**, 425–431
- Gallagher, R.P., Elwood, J.M., Hill, G.B., Coldman, A.J., Threlfall, W.J. & Spinelli, J.J. (1985) Reproductive factors, oral contraceptives and risk of malignant melanoma: Western Canada melanoma study. *Br. J. Cancer*, **52**, 901–907
- Gefeller, O., Hassan, K. & Wille, L. (1997) A meta-analysis on the relationship between oral contraceptives and melanoma: Results and methodological aspects. *J. Epidemiol. Biostat.*, **2**, 225–235
- Ghia, M. & Mereto, E. (1989) Induction and promotion of γ -glutamyltranspeptidase-positive foci in the liver of female rats treated with ethinyl estradiol, clomiphene, tamoxifen and their associations. *Cancer Lett.*, **46**, 195–202
- Ghosh, R. & Ghosh, P.K. (1988) Sister chromatid exchange in the lymphocytes of control women, pregnant women, and women taking oral contraceptives: Effects of cell culture temperature. *Environ. mol. Mutag.*, **12**, 179–183
- Gidley, J.T., Christensen, H.D., Hall, I.H., Palmer, K.H. & Wall, M.E. (1970) Teratogenic and other effects produced in mice by norethynodrel and its 3-hydroxymetabolites. *Teratology*, **3**, 339–344
- Giudice, L.C., Milkowski, D.A., Fielder, P.J. & Irwin, J.C. (1991) Characterization of the steroid-dependence of insulin-like growth factor-binding protein-2 synthesis and mRNA expression in cultured human endometrial stromal cells. *Hum. Reprod.*, **6**, 632–640
- Going, J.J., Anderson, T.J., Battersby, S. & Macintyre, C.C.A. (1988) Proliferative and secretory activity in human breast during natural and artificial menstrual cycles. *Am. J. Pathol.*, **130**, 193–204
- Goldzieher, J.W. & Brody, S.A. (1990) Pharmacokinetics of ethinyl estradiol and mestranol. *Am. J. Obstet. Gynecol.*, **163**, 2114–2119
- Goldzieher, J.W., Maas, J.M. & Hines, D.C. (1968) Seven years of clinical experience with a sequential oral contraceptive. *Int. J. Fertil.*, **13**, 399–404

- Golub, M.S., Hayes, L., Prahalada, S. & Hendrickx, A.G. (1983) Behavioral tests in monkey infants exposed embryonically to an oral contraceptive. *Neurobehav. Toxicol. Teratol.*, **5**, 301–304
- Gomes, A.L.R.R., Guimarães, M.D.C., Gomes, C.C., Chaves, I.G., Goff, H. & Camargos, A.F. (1995) A case–control study of risk factors for breast cancer in Brazil, 1978–87. *Int. J. Epidemiol.*, **24**, 292–299
- Gram, I.T., Macaluso, M. & Stalsberg, H. (1992) Oral contraceptive use and the incidence of cervical intraepithelial neoplasia. *Am. J. Obstet. Gynecol.*, **167**, 40–44
- Greb, R.R., Heikinheimo, O., Williams, R.F., Hodgson G.D. & Goodman, A.L. (1997) Vascular endothelial growth factor in primate endometrium is regulated by oestrogen-receptor and progesterone-receptor ligands *in vivo*. *Hum. Reprod.*, **12**, 1280–1292
- Green, A. & Bain, C. (1985) Hormonal factors and melanoma in women. *Med. J. Austr.*, **142**, 446–448
- Grill, H.J., Manz, B., Elger, W. & Pollow, K. (1985) 3H-Cyproterone acetate: Binding characteristics to human uterine progesterone receptors. *J. endocrinol. Invest.*, **8**, 135–141
- Gross, T.P. & Schlesselman, J.J. (1994) The estimated effect of oral contraceptive use on the cumulative risk of epithelial ovarian cancer. *Obstet. Gynecol.*, **83**, 419–424
- Gross, T.P., Schlesselman, J.J., Stadel, B.V., Yu, W. & Lee, N.C. (1992) The risk of epithelial ovarian cancer in short-term users of oral contraceptives. *Am. J. Epidemiol.*, **136**, 46–53
- Guengerich, F.P. (1988) Oxidation of 17 α -ethynylestradiol by human liver cytochrome P-450. *Mol. Pharmacol.*, **33**, 500–508
- Hackenberg, R., Hofmann, J., Hölzel, F. & Schulz, K.-D. (1988) Stimulatory effects of androgen and antiandrogen on the *in vitro* proliferation of human mammary carcinoma cells. *J. Cancer Res. clin. Oncol.*, **114**, 593–601
- Hajek, R.A., Van, N.T., Johnston, D.A. & Jones, L.A. (1993) *In vivo* induction of increased DNA ploidy of mouse cervicovaginal epithelium by neonatal estrogen treatment. *Biol. Reprod.*, **49**, 908–917
- Hallquist, A., Hardell, L., Degerman, A. & Boquist, L. (1994) Thyroid cancer: Reproductive factors, previous diseases, drug intake, family history and diet. A case–control study. *Eur. J. Cancer Prev.*, **3**, 481–488
- Hallstrom, I.P., Liao, D.-Z., Assefaw-Redda, Y., Ohlson, L.C., Sahlin, L., Eneroth, P., Eriksson, L.C., Gustafsson, J.-A. & Blanck, A. (1996) Role of the pituitary in tumor promotion with ethinyl estradiol in rat liver. *Hepatology*, **24**, 849–854
- Han, X. & Liehr, J.G. (1994) DNA single-strand breaks in kidneys of Syrian hamsters treated with steroidal estrogens: Hormone-induced free radical damage preceding renal malignancy. *Carcinogenesis*, **15**, 997–1000
- Han, X. & Liehr, J.G. (1995) Microsome-mediated 8-hydroxylation of guanine bases of DNA by steroid estrogens: Correlation of DNA damage by free radicals with metabolic activation to quinones. *Carcinogenesis*, **16**, 2571–2574
- Han, X., Liehr, J.G. & Bosland, M.C. (1995) Induction of a DNA adduct detectable by ³²P-post-labelling in the dorsolateral prostate of NBL/Cr rats treated with estradiol-17 β and testosterone. *Carcinogenesis*, **16**, 951–954

- Handy, R.W., Palmer, K.H., Wall, M.E. & Piantadosi, C. (1974) The metabolism of antifertility steroids. The *in vitro* metabolism of chlormadinone acetate. *Drug Metab. Disposition*, **2**, 214–220
- Hankinson, S.E., Colditz, G.A., Hunter, D.J., Willett, W.C., Stampfer, M.J., Rosner, B., Hennekens, C.H. & Speizer, F.E. (1995) A prospective study of reproductive factors and risk of epithelial ovarian cancer. *Cancer*, **76**, 284–290
- Hannaford, P.C., Villard-Mackintosh, L., Vessey, M.P. & Kay, C.R. (1991) Oral contraceptives and malignant melanoma. *Br. J. Cancer*, **63**, 430–433
- Hannaford, P.C., Kay, C.R., Vessey, M.P., Painter, R. & Mant, J. (1997) Combined oral contraceptives and liver disease. *Contraception*, **55**, 145–151
- Harlap, S., Shiono, P.H. & Ramcharan, S. (1985a) Congenital abnormalities in the offspring of women who used oral and other contraceptives around the time of conception. *Int. J. Fertil.*, **30**, 39–47
- Harlap, S., Shiono, P.H., Ramcharan, S., Golbus, M., Bachman, R., Mann, J. & Lewis, J.P. (1985b) Chromosomal abnormalities in the Kaiser-Permanente birth defects study, with special reference to contraceptive use around the time of conception. *Teratology*, **31**, 381–387
- Harlow, B.L., Weiss, N.S., Roth, G.J., Chu, J. & Daling, J.R. (1988) Case-control study of borderline ovarian tumors: Reproductive history and exposure to exogenous female hormones. *Cancer Res.*, **48**, 5849–5852
- Harris, R.W.C., Brinton, L.A., Cowdell, R.H., Skegg, D.C.G., Smith, P.G., Vessey, M.P. & Doll, R. (1980) Characteristics of women with dysplasia or carcinoma in situ of the cervix uteri. *Br. J. Cancer*, **42**, 359–369
- Harris, N.V., Weiss, N.S., Francis, A.M. & Polissar, L.N. (1982) Breast cancer in relation to patterns of oral contraceptive use. *Am. J. Epidemiol.*, **116**, 643–651
- Harris, R.E., Zang, E.A. & Wynder, E.L. (1990) Oral contraceptives and breast cancer risk: A case-control study. *Int. J. Epidemiol.*, **19**, 240–246
- Harris, R., Whittemore, A.S., Itnyre, J. & the Collaborative Ovarian Cancer Group (1992) Characteristics relating to ovarian cancer risk: Collaborative analysis of 12 US case-control studies. III. Epithelial tumors of low malignant potential in white women. *Am. J. Epidemiol.*, **136**, 1204–1211
- Hartge, P., Schiffman, M.H., Hoover, R., McGowan, L., Leshner, L. & Norris, H.J. (1989a) A case-control study of epithelial ovarian cancer. *Am. J. Obstet. Gynecol.*, **161**, 10–16
- Hartge, P., Tucker, M.A., Shields, J.A., Augsburger, J., Hoover, R.N. & Fraumeni, J.F., Jr (1989b) Case-control study of female hormones and eye melanoma. *Cancer Res.*, **49**, 4622–4625
- Hatcher, R.A., Rinckart, W., Blackburn, R. & Geller, J.S. (1997) *The Essentials of Contraceptive Technology*, Baltimore, Population Information Program, Center for Communication Programs, The Johns Hopkins School of Public Health, pp. 5–23
- Haukkamaa, M., Niemelä, A. & Tuohimaa, P. (1980) Progesterone-binding properties of the microsomal fraction from chick oviduct. *Mol. cell. Endocrinol.*, **19**, 123–130
- Heinecke, H. & Klaus, S. (1975) Effect of mestranol on the gravidity of mice. *Pharmazie*, **30**, 53–56 (in German)
- Heinecke, H. & Kohler, D. (1983) Prenatal toxic effects of STS557. II. Investigation in rabbits—preliminary results. *Exp. clin. Endocrinol.*, **81**, 206–209

- Hellberg, D., Valentin, J. & Nilsson, S. (1985) Long-term use of oral contraceptives and cervical neoplasia: An association confounded by other risk factors? *Contraception*, **32**, 337–346
- Helmrich, S.P., Rosenberg, L., Kaufman, D.W., Miller, D.R., Schottenfeld, D., Stolley, P.D. & Shapiro, S. (1984) Lack of an elevated risk of malignant melanoma in relation to oral contraceptive use. *J. natl Cancer Inst.*, **72**, 617–620
- Henderson, B.E., Casagrande, J.T., Pike, M.C., Mack, T., Rosario, I. & Duke, A. (1983a) The epidemiology of endometrial cancer in young women. *Br. J. Cancer*, **47**, 749–756
- Henderson, B., Preston-Martin, S., Edmonson, H.A., Peters, R.L. & Pike, M.C. (1983b) Hepatocellular carcinoma and oral contraceptives. *Br. J. Cancer*, **48**, 437–440
- Hennekens, C.H., Speizer, F.E., Lipnick, R.J., Rosner, B., Bain, C., Belanger, C., Stampfer, M.J., Willett, W. & Peto, R. (1984) A case-control study of oral contraceptive use and breast cancer. *J. natl Cancer Inst.*, **72**, 39–42
- Heuner, A., Kuhn, W., Heger-Mahn, D., Richert, K. & Hümpel, M. (1995) A single-dose and 3-month clinical-pharmacokinetic study with a new combination oral contraceptive. *Adv. Contracept.*, **11**, 207–225
- Hildesheim, A., Gravitt, P., Schiffman, M.H., Kurman, R.J., Barnes, W., Jones, S., Tchabo, J.-G., Brinton, L.A., Copeland, C., Epp, J. & Manos, M.M. (1993) Determinants of genital human papillomavirus infection in low-income women in Washington, DC. *Sex. transm. Dis.*, **20**, 279–285
- Hildesheim, A., Schiffman, M.H., Gravitt, P.E., Glass, A.G., Greer, C.E., Zhang, T., Scott, D.R., Rush, B.B., Lawler, P., Sherman, M.E., Kurman, R.J. & Manos, M.M. (1994) Persistence of type-specific human papillomavirus infection among cytologically normal women. *J. infect. Dis.*, **169**, 235–240
- Hildreth, N.G., Kelsey, J.L., LiVolsi, V.A., Fischer, D.B., Holford, T.R., Mostow, E.D., Schwartz, P.E. & White, C. (1981) An epidemiologic study of epithelial carcinoma of the ovary. *Am. J. Epidemiol.*, **114**, 398–405
- Hill, A. & Wolff, S. (1983) Sister chromatid exchanges and cell division delays induced by diethylstilbestrol, estradiol, and estriol in human lymphocytes. *Cancer Res.*, **43**, 4114–4118
- Hill, L., Murphy, M., McDowall, M. & Paul, A.H. (1988) Maternal drug histories and congenital malformations: Limb reduction defects and oral clefts. *J. Epidemiol. Community Health*, **42**, 1–7
- Hillbertz-Nilsson, K. & Forsberg, J.-G. (1985) Estrogen effects on sister chromatid exchanges in mouse uterine cervical and kidney cells. *J. natl Cancer Inst.*, **75**, 575–580
- Ho, G.Y.F., Burk, R.D., Klein, S., Kadish, A.S., Chang, C.J., Palan, P., Basu, J., Tachezy, R., Lewis, R. & Romney, S. (1995) Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. *J. natl Cancer Inst.*, **87**, 1365–1371
- Ho, G.Y.F., Bierman, R., Beardsley, L., Chang, C.J. & Burk, R.D. (1998) Natural history of cervicovaginal papillomavirus infection in young women. *New Engl. J. Med.*, **338**, 423–428
- Hoffmann, H., Hillesheim, H.G., Güttner, J., Stade, K., Merbt, E.-M. & Holle, K. (1983) Long-term toxicological studies on the progestin STS 557. *Exp. clin. Endocrinol.*, **81**, 179–196
- Holly, E.A., Weiss, N.S. & Liff, J.M. (1983) Cutaneous melanoma in relation to exogenous hormones and reproductive factors. *J. natl Cancer Inst.*, **70**, 827–831

- Holly, E.A., Cress, R.D. & Ahn, D.K. (1994) Cutaneous melanoma in women: Ovulatory life, menopause, and use of exogenous oestrogens. *Cancer Epidemiol. Biomarkers Prev.*, **3**, 661–668
- Holly, E.A., Cress, R.D. & Ahn, D.K. (1995) Cutaneous melanoma in women. III. Reproductive factors and oral contraceptive use. *Am. J. Epidemiol.*, **141**, 943–950
- Holmberg, L., Lund, E., Bergström, R., Adami, H.-O. & Meirik, O. (1994) Oral contraceptives and prognosis in breast cancer: Effects of duration, latency, recency, age at first use and relation to parity and body mass index in young women with breast cancer. *Eur. J. Cancer*, **30A**, 351–354
- Holtzman, S. (1988) Retinyl acetate inhibits estrogen-induced mammary carcinogenesis in female ACI rats. *Carcinogenesis*, **9**, 305–307
- Homady, M.H., Al-Khayat, T.H.A. & Brain, P.F. (1986) Effects of different doses of cyproterone acetate (CA) on preputial gland structure and activity in intact male mice. *Comp. Biochem. Physiol.*, **85C**, 187–191
- Honoré, L.H., Koch, M. & Brown, L.B. (1991) Comparison of oral contraceptive use in women with adenocarcinoma and squamous cell carcinoma of the uterine cervix. *Gynecol. obstet. Invest.*, **32**, 98–101
- Hopkins, M.P. & Morley, G.W. (1991) A comparison of adenocarcinoma and squamous cell carcinoma of the cervix. *Obstet. Gynecol.*, **77**, 912–917
- Horn-Ross, P.L., Whittemore, A.S., Harris, R., Itnyre, J. & the Collaborative Ovarian Cancer Group (1992) Characteristics relating to ovarian cancer risk: Collaborative analysis of 12 US case-control studies. VI. Nonepithelial cancers among adults. *Epidemiology*, **3**, 490–495
- Hsing, A.W., Hoover, R.N., McLaughlin, J.K., Co-Chien, H.T., Wacholder, S., Blot, W.J. & Fraumeni, J.F. (1992) Oral contraceptives and primary liver cancer among young women. *Cancer Causes Control*, **3**, 43–48
- Huber, J., Zeillinger, R., Schmidt, J., Täuber, U., Kuhn, W. & Spona, J. (1988) Pharmacokinetics of cyproterone acetate and its main metabolite 15 β -hydroxy-cyproterone acetate in young healthy women. *Int. J. clin. Pharmacol. Ther. Toxicol.*, **26**, 555–561
- Hulka, B.S., Chambless, L.E., Kaufman, D.G., Fowler, W.C., Jr & Greenberg, B.G. (1982) Protection against endometrial carcinoma by combination-product oral contraceptives. *J. Am. med. Assoc.*, **247**, 475–477
- Hümpel, M., Täuber, U., Kuhn, W., Pfeffer, M., Brill, K., Heithecker, R., Louton, T. & Steinberg, B. (1990) Comparison of serum ethinyl estradiol, sex-hormone-binding globulin, corticoid-binding globulin and cortisol levels in women using two low-dose combined oral contraceptives. *Hormone Res.*, **33**, 35–39
- Hussain, S.P. & Rao, A.R. (1992) Modulatory influence of oral contraceptive pills Ovral and Noracycline on 3-methylcholanthrene-induced carcinogenesis in the uterine cervix of mouse. *Jpn. J. Cancer Res.*, **83**, 576–583
- Hussain, S.P., Chhabra, S.K. & Rao, A.R. (1991) Effects of oral contraceptive pills on drug metabolizing enzymes and acid soluble sulfhydryl level in mouse liver. *Biochem. int.*, **25**, 973–984
- Husum, B., Wulf, H.C. & Niebuhr, E. (1982) Normal sister-chromatid exchanges in oral contraceptive users. *Mutat. Res.*, **103**, 161–164
- Hyder, S.M., Murthy, L. & Stancel, G.M. (1998) Progestin regulation of vascular endothelial growth factor in human breast cancer cells. *Cancer Res.*, **58**, 392–395

- IARC (1974) *IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man*, Vol. 6, *Sex Hormones*, Lyon
- IARC (1979) *IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans*, Vol. 21, *Sex Hormones (II)*, Lyon, pp. 105–106
- IARC (1987) *IARC Monographs on the Evaluation of the Carcinogenic Risks to Humans*, Suppl. 7, *Overall Evaluations of Carcinogenicity: An Updating of IARC Monographs Volumes 1–42*, pp. 272–310
- IARC (1988) *IARC Monographs on the Evaluation of Carcinogenic Risks to Humans*, Vol. 44, *Alcohol Drinking*, Lyon
- IARC (1994) *IARC Monographs on the Evaluation of Carcinogenic Risks to Humans*, Vol. 59, *Hepatitis Viruses*, Lyon
- IARC (1995) *IARC Monographs on the Evaluation of Carcinogenic Risks to Humans*, Vol. 64, *Human Papillomaviruses*, Lyon
- Ingerowski, G.H., Scheutwinkel-Reich, M. & Stan, H.-J. (1981) Mutagenicity studies on veterinary anabolic drugs with the *Salmonella*/microsome test. *Mutat. Res.*, **91**, 93–98
- Iqbal, M.J. & Colletta, A.A. (1987) Characterisation of gestodene binding to the oestrogen receptor in human malignant breast tissue. *Anticancer Res.*, **7**, 45–48
- Iqbal, M.J. & Valyani, S.H. (1988) Evidence for a novel binding site for the synthetic progestogen, gestodene on oestrogen receptor in human malignant tissue. *Anticancer Res.*, **8**, 351–354
- Iqbal, M.J., Colletta, A.A., Houmayoun-Valyani, S.D. & Baum, M. (1986) Differences in oestrogen receptors in malignant and normal breast tissue as identified by the binding of a new synthetic progestogen. *Br. J. Cancer*, **54**, 447–452
- Irwin, K.L., Rosero-Bixby, L., Oberle, M.W., Lee, N.C., Whatley, A.S., Fortney, J.A. & Bonhomme, M.G. (1988) Oral contraceptives and cervical cancer risk in Costa Rica. *J. Am. med. Assoc.*, **259**, 59–64
- Ishidate, M., Jr, ed. (1983) *The Data Book of Chromosomal Aberration Tests in Vitro on 587 Chemical Substances using a Chinese Hamster Fibroblast Cell Line (CHL Cells)*, Tokyo, Realize
- Ishidate, M., Jr, Hayashi, M., Sawada, M., Matsuoka, A., Yoshikawa, K., Ono, M. & Nakadate, M. (1978) Cytotoxicity test on medical drugs—Chromosome aberration tests with Chinese hamster cells *in vitro*. *Eisei Shikenjo Hokoku*, **96**, 55–61 (in Japanese)
- Jacobs, E.J., White, E. & Weiss, N.S. (1994) Exogenous hormones, reproductive history, and colon cancer (Seattle, Washington, United States). *Cancer Causes Control*, **5**, 359–366
- Jacobson, J.S., Neugut, A.I., Garbowski, G.D., Ahsan, H., Wayne, J.D., Treat, M.R. & Forde, K.A. (1995) Reproductive risk factors for colorectal adenomatous polyps (New York City, NY, United States). *Cancer Causes Control*, **6**, 513–518
- Janerich, D.T., Flink, E.M. & Keogh, M.D. (1976) Down's syndrome and oral contraceptive usage. *Br. J. Obstet. Gynaecol.*, **83**, 617–620
- Janerich, D.T., Polednak, A.P., Glebatis, D.M. & Lawrence, C.E. (1983) Breast cancer and oral contraceptive use: A case-control study. *J. chron. Dis.*, **36**, 639–646
- Jean-Faucher, C., Berger, M., de Turckheim, M., Veyssiere, G. & Jean, C. (1985) Permanent changes in the functional development of accessory sex organs and in fertility in male mice after neonatal exposure to cyproterone acetate. *J. Endocrinol.*, **104**, 113–120

- Jeng, M.-H. & Jordan, V.C. (1991) Growth stimulation and differential regulation of transforming growth factor- β 1 (TGF β 1), TGF β 2, and TGF β 3 messenger RNA levels by norethindrone in MCF-7 human breast cancer cells. *Mol. Endocrinol.*, **8**, 1120–1128
- Jeng, M.-H., Parker, C.J. & Jordan, V.C. (1992) Estrogenic potential of progestins in oral contraceptives to stimulate human breast cancer cell proliferation. *Cancer Res.*, **52**, 6539–6546
- Jiang, S.-Y., Shyu, R.-Y., Yeh, M.-Y. & Jordan, V.C. (1995) Tamoxifen inhibits hepatoma cell growth through an estrogen receptor independent mechanism. *J. Hepatol.*, **23**, 712–719
- Jick, H., Walker, A.M., Watkins, R.N., Dewart, D.C., Hunter, J.R., Danford, A., Madsen, S., Dinan, B.J. & Rothman, K.J. (1980) Oral contraceptives and breast cancer. *Am. J. Epidemiol.*, **112**, 577–585
- Jick, S.S., Walker, A.M., Stergachis, A. & Jick, H. (1989) Oral contraceptives and breast cancer. *Br. J. Cancer*, **59**, 618–621
- Jick, S.S., Walker, A.M. & Jick, H. (1993) Oral contraceptives and endometrial cancer. *Obstet. Gynecol.*, **82**, 931–935
- Jick, H., Jick, S.S., Gurewich, V., Myers, M.W. & Vasilakis, C. (1995) Risk of idiopathic cardiovascular death and non-fatal venous thromboembolism in women using oral contraceptives with differing progestagen components. *Lancet*, **346**, 1589–1593
- John, E.M., Whittemore, A.S., Harris, R., Itnyre, J. & Collaborative Ovarian Cancer Group (1993) Characteristics relating to ovarian cancer risk: Collaborative analysis of seven US case-control studies. Epithelial ovarian cancer in black women. *J. natl Cancer Inst.*, **85**, 142–147
- Jones, M.W. & Silverberg, S.G. (1989) Cervical adenocarcinoma in young women: Possible relationship to microglandular hyperplasia and use of oral contraceptives. *Obstet. Gynecol.*, **73**, 984–989
- Jones, C.J., Brinton, L.A., Hamman, R.F., Stolley, P.D., Lehman, H.F., Levine, R.S. & Mallin, K. (1990) Risk factors for in situ cervical cancer: Results from a case-control study. *Cancer Res.*, **50**, 3657–3662
- Juchem, M. & Pollow, K. (1990) Binding of oral contraceptive progestogens to serum proteins and cytoplasmic receptor. *Am. J. Obstet. Gynecol.*, **163**, 2171–2183
- Juchem, M., Pollow, K., Elger, W., Hoffmann, G. & Möbus, V. (1993) Receptor binding of norgestimate—a new orally active synthetic progestational compound. *Contraception*, **47**, 283–294
- Kalandidi, A., Tzonon, A., Lipworth, L., Garnatsi, L., Filippa, D. & Trichopoulos, D. (1996) A case-control study of endometrial cancers in relation to reproductive, somatometric and lifestyle variables. *Oncology*, **53**, 354–359
- Kalkhoven, E., Kwakkenbos-Isbrücker, L., de Laat, S.W., van der Saag, P.T. & van der Burg, B. (1994) Synthetic progestins induce proliferation of breast tumor cell lines via the progesterone or estrogen receptor. *Mol. cell. Endocrinol.*, **102**, 45–52
- Kalkhoven, E., Beraldi, E., Panno, M.L., De Winter, J.P., Thijssen, J.H.H. & van der Burg, B. (1996) Growth inhibition by anti-estrogens and progestins in TGF- β -resistant and -sensitive breast-tumor cells. *Int. J. Cancer*, **65**, 682–687
- Källén, B. (1989) Maternal use of contraceptives and Down syndrome. *Contraception*, **39**, 503–505

- Källén, B., Mastroiacovo, P., Lancaster, P.A.L., Mutchinick, O., Kringelback, M., Martínez-Frías, M.L., Robert, E. & Castilla, E.E. (1991) Oral contraceptives in the etiology of isolated hypospadias. *Contraception*, **44**, 173–182
- Kampman, E., Potter, J.D., Slattery, M.L., Caan, B.J. & Edward, S. (1997) Hormone replacement therapy, reproductive history, and colon cancer: A multicenter, case-control study in the United States. *Cancer Causes Control*, **8**, 146–158
- Kappus, H., Bolt, H.M. & Remmer, H. (1973) Affinity of ethynyl-estradiol and mestranol for the uterine estrogen receptor and for the microsomal mixed function oxidase of the liver. *J. Steroid Biochem.*, **4**, 121–128
- Kasid, A. & Laumas, K.R. (1981) Nuclear progesterin receptors in human uterus. *Endocrinology*, **109**, 553–560
- Kasper, P. & Mueller, L. (1996) Time-related induction of DNA repair synthesis in rat hepatocytes following *in vivo* treatment with cyproterone acetate. *Carcinogenesis*, **17**, 2271–2274
- Kasper, P., Tegethoff, K. & Mueller, L. (1995) *In vitro* mutagenicity studies on cyproterone acetate using female rat hepatocytes for metabolic activation and as indicator cells. *Carcinogenesis*, **16**, 2309–2314
- Kästner, D. & Apfelbach, R. (1987) Effects of cyproterone acetate on mating behaviour, testicular morphology, testosterone level, and body temperature in male ferrets in comparison with normal and castrated males. *Horm. Res.*, **25**, 178–184
- Kaufman, R.H., Reeves, K.O. & Dougherty, C.M. (1976) Severe atypical endometrial changes and sequential contraceptive use. *J. Am. med. Assoc.*, **236**, 923–926
- Kaufman, D.W., Shapiro, S., Slone, D., Rosenberg, L., Miettinen, O.S., Stolley, P.D., Knapp, R.C., Leavitt, T., Jr, Watring, W.G., Rosenshein, N.B., Lewis, J.L., Jr, Schottenfeld, D. & Engle, R.L., Jr (1980) Decreased risk of endometrial cancer among oral-contraceptive users. *New Engl. J. Med.*, **303**, 1045–1047
- Kaur, J., Ramakrishnan, P.R. & Rajalakshmi, M. (1990) Inhibition of spermatozoa maturation in rhesus monkey by cyproterone acetate. *Contraception*, **42**, 349–359
- Kaur, J., Ramakrishnan, P.R. & Rajalakshmi, M. (1992) Effect of cyproterone acetate on structure and function of rhesus monkey reproductive organs. *Anat. Rec.*, **234**, 62–72
- Kawashima, K., Nakaura, S., Nagao, S., Tanaka, S., Kawamura, T. & Omori, Y. (1977) Virilizing activities of various steroids in female rat fetuses. *Endocrinol. Jpn.*, **24**, 77–81
- Kay, C.R. (1981) Malignant melanoma and oral contraceptives (Letter to the Editor). *Br. J. Cancer*, **44**, 479
- Kay, C.R. & Hannaford, P.C. (1988) Breast cancer and the pill—A further report from the Royal College of General Practitioners' oral contraceptive study. *Br. J. Cancer*, **58**, 675–680
- Kelsey, J.L., Holford, T.R., White, C., Mayer, E.S., Kilty, S.E. & Acheson, R.M. (1978) Oral contraceptives and breast disease. An epidemiological study. *Am. J. Epidemiol.*, **107**, 236–244
- Kelsey, J.L., LiVolsi, V.A., Holford, T.R., Fischer, D.B., Mostow, E.D., Schwartz, P.E., O'Connor, T. & White, C. (1982) A case-control study of cancer of the endometrium. *Am. J. Epidemiol.*, **116**, 333–342
- Kennedy, A.R. & Weichselbaum, R.R. (1981) Effects of 17β -estradiol on radiation transformation *in vitro*; inhibition of effects by protease inhibitors. *Carcinogenesis*, **2**, 67–69

- Kennelly, J.J. (1969) The effect of mestranol on canine reproduction. *Biol. Reprod.*, **1**, 282–288
- Kerdar, R.S., Baumann, A., Brudny-Klöppel, M., Biere, H., Blode, H. & Kuhnz, W. (1995) Identification of 3 α -hydroxy-cyproterone acetate as a metabolite of cyproterone acetate in the bile of female rats and the potential of this and other already known or putative metabolites to form DNA adducts *in vitro*. *Carcinogenesis*, **16**, 1835–1841
- Kew, M.C., Song, E., Mohammed, A. & Hodgkinson, J. (1990) Contraceptive steroids as a risk factor for hepatocellular carcinoma: A case-control study in South African black women. *Hepatology*, **11**, 298–302
- Kiivet, R.A., Bergman, U., Rootslane, L., Rago, L. & Sjoqvist, F. (1998) Drug use in Estonia in 1994–1995: A follow-up from 1989 and comparison with two Nordic countries. *Eur. J. clin. Pharmacol.*, **54**, 119–124
- Killinger, J., Hahn, D.W., Phillips, A., Hetyei, N.S. & McGuire, J.L. (1985) The affinity of norgestimate for uterine progesterone receptors and its direct action on the uterus. *Contraception*, **32**, 311–319
- King, R.J.B. (1991) Biology of female sex hormone action in relation to contraceptive agents and neoplasia. *Contraception*, **43**, 527–542
- Kjaer, S.K., Engholm, G., Dahl, C., Bock, J.E., Lynge, E. & Jensen, O.M. (1993) Case-control study of risk factors for cervical squamous-cell neoplasia in Denmark. III. Role of oral contraceptive use. *Cancer Causes Control*, **4**, 513–519
- Kleinman, R.L. (1990) *Hormonal Contraception*, London, IPPF Medical Publications
- Kleinman, R.L. (1996) *Directory of Hormonal Contraceptives*, London, IPPF Medical Publications
- Kloosterboer, H.J., Vonk-Noordegraaf, C.A. & Turpijn, E.W. (1988) Selectivity in progesterone and androgen receptor binding of progestagens used in oral contraceptives. *Contraception*, **38**, 325–332
- Kolonel, L.N., Hankin, J.H., Wilkens, L.R., Fukunaga, F.H. & Hinds, M.W. (1990) An epidemiologic study of thyroid cancer in Hawaii. *Cancer Causes Control*, **1**, 223–234
- Kontula, K., Paavonen, T., Luukkainen, T. & Andersson, L.C. (1983) Binding of progestins to the glucocorticoid receptor. Correlation to their glucocorticoid-like effects on *in vitro* functions of human mononuclear leukocytes. *Biochem. Pharmacol.*, **32**, 1511–1518
- Koper, N.P., Kiemeny, L.A.L.M., Massuger, L.F.A.G., Thomas, C.M.G., Schijf, C.P.T. & Verbeek, A.L.M. (1996) Ovarian cancer incidence (1989–1991) and mortality (1954–1993) in The Netherlands. *Obstet. Gynecol.*, **88**, 387–393
- Kopera, H. (1985) Unintended effects of oral contraceptives. II. Progesterone-caused effects, interactions with drugs. *Wien med. Wochenschr.*, **17**, 415–419 (in German)
- van Kordelaar, J.M.G., Vermorken, A.J.M., de Weerd, C.J.M. & van Rossum, J.M. (1975) Interaction of contraceptive progestins and related compounds with the oestrogen receptor. Part II: Effect on (3H)oestradiol binding to the rat uterine receptor *in vitro*. *Acta endocrinol.*, **78**, 165–179
- Koumantaki, Y., Tzonou, A., Koumantakis, E., Kaklamani, E., Aravantinos, D. & Trichopoulos, D. (1989) A case-control study of cancer of endometrium in Athens. *Int. J. Cancer*, **43**, 795–799

- Koutsky, L.A., Holmes, K.K., Critchlow, C.S., Stevens, C.E., Paavonen, J., Beckmann, A.M., DeRouen, T.A., Galloway, D.A., Vernon, D. & Kiviat, N.B. (1992) A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. *New Engl. J. Med.*, **327**, 1272–1278
- Krebs, O., Schäfer, B., Wolff, T., Oesterle, D., Deml, E., Sund, M. & Favor, J. (1998) The DNA damaging drug cyproterone acetate causes gene mutations and induces glutathione-S-transferase P in the liver of female Big Blue™ transgenic F344 rats. *Carcinogenesis*, **19**, 241–245
- Kreitmann, B., Bugat, R. & Bayard, F. (1979) Estrogen and progestin regulation of the progesterone receptor concentration in human endometrium. *J. clin. Endocrinol. Metab.*, **49**, 926–929
- Kuhl, H. (1990) Pharmacokinetics of oestrogens and progestogens. *Maturitas*, **12**, 171–197
- Kuhl, H., Jung-Hoffmann, C. & Wiegatz, I. (1995) Gestodene-containing contraceptives. *Clin. Obstet. Gynecol.*, **38**, 829–840
- Kuhnz, W. & Beier, S. (1994) Comparative progestational and androgenic activity of norgestimate and levonorgestrel in the rat. *Contraception*, **49**, 275–289
- Kuhnz, W. & Löfberg, B. (1995) Urinary excretion of 6 β -hydroxycortisol in women during treatment with different oral contraceptive formulations. *J. Steroid Biochem. mol. Biol.*, **55**, 129–133
- Kuhnz, W., Hümpel, M., Schütt, B., Louton, T., Steinberg, B. & Gansau, C. (1990a) Relative bioavailability of ethinyl estradiol from two different oral contraceptive formulations after single oral administration to 18 women in an intraindividual cross-over design. *Hormone Res.*, **33**, 40–44
- Kuhnz, W., Pfeffer, M. & Al-Yacoub, G. (1990b) Protein binding of the contraceptive steroids gestodene, 3-keto-desogestrel and ethinylestradiol in human serum. *J. Steroid Biochem.*, **35**, 313–318
- Kuhnz, W., Sostarek, D., Gansau, C. & Louton, T. (1991) Single and multiple administration of a new triphasic oral contraceptive to women: Pharmacokinetics of ethinylestradiol and free and total testosterone levels in serum. *Am. J. Obstet. Gynecol.*, **165**, 596–602
- Kuhnz, W., Al-Yacoub, G. & Fuhrmeister, A. (1992) Pharmacokinetics of levonorgestrel and ethinylestradiol in 9 women who received a low-dose oral contraceptive over a treatment period of 3 months and, after a wash-out phase, a single oral administration of the same contraceptive formulation. *Contraception*, **46**, 455–469
- Kuhnz, W., Staks, T. & Jütting, G. (1993a) Pharmacokinetics of cyproterone acetate and ethinylestradiol in 15 women who received a combination oral contraceptive during three treatment cycles. *Contraception*, **48**, 557–575
- Kuhnz, W., Baumann, A., Staks, T., Dibbelt, L., Knuppen, R. & Jütting, G. (1993b) Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: Serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum. *Contraception*, **48**, 303–322
- Kuhnz, W., Staks, T. & Jütting, G. (1994a) Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: Serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum. *Contraception*, **50**, 563–579

- Kuhnz, W., Blode, H. & Mahler, M. (1994b) Systemic availability of levonorgestrel after single oral administration of a norgestimate-containing combination oral contraceptive to 12 young women. *Contraception*, **49**, 255–263
- Kuhnz, W., Fritzemeier, K.H., Hegele-Hartung, C. & Krattenmacher, R. (1995) Comparative progestational activity of norgestimate, levonorgestrel-oxime and levonorgestrel in the rat and binding of these compounds to the progesterone receptor. *Contraception*, **51**, 131–139
- Kumar, M.V. & Panda, J.N. (1983) Epididymal histoarchitecture of goats under chronic cyproterone acetate. *Andrologia*, **15**, 193–195
- Kumasaka, T., Itoh, E., Watanabe, H., Hoshino, K., Yoshinaka, A. & Masawa, N. (1994) Effects of various forms of progestin on the endometrium of the estrogen-primed, ovariectomized rat. *Endocrine J.*, **41**, 161–169
- Kune, G.A., Kune, S. & Watson, L.F. (1990) Oral contraceptive use does not protect against large bowel cancer. *Contraception*, **41**, 19–25
- Kwapien, R.P., Giles, R.C., Geil, R.G. & Casey, H.W. (1980) Malignant mammary tumors in beagle dogs dosed with investigational oral contraceptive steroids. *J. natl Cancer Inst.*, **65**, 137–144
- Labrie, C., Cusan, L., Plante, M., Lapointe, S. & Labrie, F. (1987) Analysis of the androgenic activity of synthetic 'progestins' currently used for the treatment of prostate cancer. *J. Steroid Biochem.*, **28**, 379–384
- Lachnit-Fixson, U. (1996) The role of triphasic levonorgestrel in oral contraception: A review of metabolic and hemostatic effects. *Gynecol. Endocrinol.*, **10**, 207–218
- Lammer, E.J. & Cordero, J.F. (1986) Exogenous sex hormone exposure and the risk of major malformations. *J. Am. med. Assoc.*, **255**, 3128–3132
- Lande, R.E. (1995) New era for injectables. *Popul. Rep.*, **23**, 1–31
- Landgren, B.M., Dada, O., Aedo, A.R., Johannisson, E. & Diczfalusy, E. (1990) Pituitary, ovarian and endometrial effects of 300 micrograms norethisterone and 30 micrograms levonorgestrel administered on cycle days 7 to 10. *Contraception*, **41**, 569–581
- Lang, R. & Redmann, U. (1979) Non-mutagenicity of some sex hormones in the Ames *Salmonella*/microsome mutagenicity test. *Mutat. Res.*, **67**, 361–365
- Lang, R. & Reimann, R. (1993) Studies for a genotoxic potential of some endogenous and exogenous sex steroids. *Environ. mol. Mutag.*, **21**, 272–304
- Larsson-Cohn, U. (1970) Contraceptive treatment with low doses of gestagens. *Acta endocrinol.*, **144** (Suppl.), 7–46
- La Vecchia, C., Decarli, A., Fasoli, M., Franceschi, S., Gentile, A., Negri, E., Parazzini, F. & Tognoni, G. (1986) Oral contraceptives and cancers of the breast and of the female genital tract. Interim results from a case-control study. *Br. J. Cancer*, **54**, 311–317
- La Vecchia, C., Parazzini, F., Negri, E., Boyle, P., Gentile, A., Decarli, A. & Franceschi, S. (1989) Breast cancer and combined oral contraceptives: An Italian case-control study. *Eur. J. Cancer clin. Oncol.*, **25**, 1613–1618
- La Vecchia, C., Lucchini, F., Negri, E., Boyle, P., Maisonneuve, P. & Levi, F. (1992) Trends of cancer mortality in Europe, 1955–1989: III. Breast and genital sites. *Eur. J. Cancer*, **28A**, 927–998

- La Vecchia, C., D'Avanzo, B., Franceschi, S., Negri, E., Parazzini, F. & Decarli, A. (1994) Menstrual and reproductive factors and gastric-cancer risk in women. *Int. J. Cancer*, **59**, 761–764
- La Vecchia, C., Negri, E., Franceschi, S., Talamini, R., Amadori, D., Filiberti, R., Conti, E., Montella, M., Veronesi, A., Parazzini, F., Ferraroni, M. & Decarli, A. (1995) Oral contraceptives and breast cancer: A cooperative Italian study. *Int. J. Cancer*, **60**, 163–167
- La Vecchia, C., Tavani, A., Franceschi, S. & Parazzini, F. (1996) Oral contraceptives and cancer. *Drug Saf.*, **14**, 260–272
- La Vecchia, C., Negri, E., Levi, F., Decarli, A. & Boyle, P. (1998) Cancer mortality in Europe: Effects of age, cohort of birth and period of death. *Eur. J. Cancer*, **34**, 118–141
- Lax, E.R. (1987) Mechanisms of physiological and pharmacological sex hormone action on the mammalian liver. *J. Steroid Biochem.*, **27**, 1119–1128
- Lax, E.R., Baumann, P. & Schriefers, H. (1984) Changes in the activities of microsomal enzymes involved in hepatic steroid metabolism in the rat after administration of androgenic, estrogenic, progestational, anabolic and catatoxic steroids. *Biochem. Pharmacol.*, **33**, 1235–1241
- Lê, M.G., Cabanes, P.A., Desvignes, V., Chanteau, M.F., Mlika, N. & Avril, M.F. (1992) Oral contraceptive use and risk of cutaneous malignant melanoma in a case-control study of French women. *Cancer Causes Control*, **3**, 199–205
- Lee, G.-H., Nomura, K. & Kitagawa, T. (1989) Comparative study of diethylnitrosamine-initiated two-stage hepatocarcinogenesis in C3H, C57BL and BALB mice promoted by various hepatopromoters. *Carcinogenesis*, **10**, 2227–2230
- Lees, A.W., Burns, P.E. & Grace, M. (1978) Oral contraceptives and breast disease in premenopausal northern Albertan women. *Int. J. Cancer*, **22**, 700–707
- Lejeune, J. & Prieur, M. (1979) Oral contraceptives and trisomy 21. A retrospective study of 730 cases. *Ann. Génét.*, **22**, 61–66 (in French)
- Lemus, A.E., Vilchis, F., Damsky, R., Chavez, B.A., Garcia, G.A., Grillasca, I. & Perez-Palacios, G. (1992) Mechanism of action of levonorgestrel: In vitro metabolism and specific interactions with steroid receptors in target organs. *J. Steroid. Biochem. mol. Biol.*, **41**, 881–890
- Lepage, F. & Gueguen, J. (1968) Results of a study on the possible teratogenic effects of chlormadinone and its possible action on the course of pregnancy. *Bull. Soc. fed. Gynecol. Obstet.*, **20** (Suppl.), 313–314 (in French)
- Levi, F., Gutzwiller, F., Decarli, A. & La Vecchia, C. (1987) Oral contraceptive use and breast and ovarian cancer mortality in Switzerland. *J. Epidemiol. Community Health*, **41**, 267–268
- Levi, F., La Vecchia, C., Gulie, C., Negri, E., Monnier, V., Franceschi, S., Delaloye, J.-F. & De Grandi, P. (1991) Oral contraceptives and the risk of endometrial cancer. *Cancer Causes Control*, **2**, 99–103
- Levi, F., Franceschi, S., Gulie, C., Negri, E. & La Vecchia, C. (1993) Female thyroid cancer: The role of reproductive and hormonal factors in Switzerland. *Oncology*, **50**, 309–315
- Levi, F., Lucchini, F., Pasche, C. & La Vecchia, C. (1996) Oral contraceptives, menopausal hormone replacement treatment and breast cancer risk. *Eur. J. Cancer Prev.*, **5**, 295–266
- Lew, R.A., Sober, A.J., Cook, N., Marvell, R. & Fitzpatrick, T.B. (1983) Sun exposure habits in patients with cutaneous melanoma: A case-control study. *J. Dermatol. surg. Oncol.*, **9**, 981–986

- Ley, C., Bauer, H.M., Reingold, A., Schiffman, M.H., Chamber, J.C., Tashiro, C.J. & Manos, M.M. (1991) Determinants of genital human papillomavirus infection in young women. *J. natl Cancer Inst.*, **83**, 997–1003
- Li, J.J. & Li, S.A. (1984) Estrogen-induced tumorigenesis in hamsters: Roles for hormonal and carcinogenic activity. *Arch. Toxicol.*, **55**, 110–118
- Li, J.J., Gonzalez, A., Banerjee, S., Banerjee, S.K. & Li, S.A. (1993) Estrogen carcinogenesis in the hamster kidney: Role of cytotoxicity and cell proliferation. *Environ. Health Perspectives*, **101** (Suppl, 5), 259–264
- Liehr, J.G., Avitts, T.A., Randerath, E. & Randerath, K. (1986) Estrogen-induced endogenous DNA adduction: Possible mechanism of hormonal cancer. *Proc. natl Acad. Sci. USA*, **83**, 5301–5305
- Liehr, J.G., Purdy, R.H., Baran, J.S., Nutting, E.F., Colton, F., Randerath, E. & Randerath, K. (1987a) Correlation of aromatic hydroxylation of 11 β -substituted estrogens with morphological transformation *in vitro* but not with *in vivo* tumour induction by these hormones. *Cancer Res.*, **47**, 2583–2588
- Liehr, J.G., Hall, E.R., Avitts, T.A., Randerath, E. & Randerath, K. (1987b) Localisation of estrogen-induced DNA adducts and cytochrome P-450 activity at the site of renal carcinogenesis in the hamster kidney. *Cancer Res.*, **47**, 2156–2159
- Lindblad, P., Mellemggaard, A., Schlehofer, B., Adami, H.-O., McCredie, M., McLaughlin, J.K. & Mandel, J.S. (1995) International renal-cell cancer study. V. Reproductive factors, gynecologic operations and exogenous hormones. *Int. J. Cancer*, **61**, 192–198
- Lipnick, R.J., Buring, J.E., Hennekens, C.H., Rosner, B., Willett, W., Bain, C., Stampfer, M.J., Colditz, G.A., Peto, R. & Speizer, F.E. (1986) Oral contraceptives and breast cancer. A prospective cohort study. *J. Am. med. Assoc.*, **255**, 58–61
- Lippman, M., Bolan, G. & Huff, K. (1976) The effects of androgens and antiandrogens on hormone-responsive human breast cancer in long-term tissue culture. *Cancer Res.*, **36**, 4610–4618
- Lipworth, L., Katsouyanni, K., Stuver, S., Samoli, E., Hankinson, S.E. & Trichopolous, D. (1995) Oral contraceptives, menopausal estrogens, and the risk of breast cancer: A case-control study in Greece. *Int. J. Cancer*, **62**, 548–551
- Liu, T., Soong, S., Alvarez, R.D. & Butterworth, C.E., Jr (1995) A longitudinal analysis of human papillomavirus 16 infection, nutritional status, and cervical dysplasia progression. *Cancer Epidemiol. Biomarkers Prev.*, **4**, 373–380
- Logan, J., Diamond, M.P., Lavy, G. & DeCherney, A.H. (1989) Effect of norgestrel on development of mouse pre-embryos. *Contraception*, **39**, 555–561
- Lohiya, N.K. & Arya, M. (1981) Oestrogenic activity of cyproterone acetate in female mice. *Endokrinologie*, **78**, 21–27
- Lohiya, N.K., Sharma, O.P., Sharma, R.C. & Sharma, R.S. (1987) Reversible sterility by cyproterone acetate plus testosterone enanthate in langur monkey with maintenance of libido. *Biomed. biochim. Acta*, **46**, 259–266
- Lu, L.W., Liehr, J.G., Sirbasku, D.A., Randerath, E. & Randerath, K. (1988) Hypomethylation of DNA in estrogen-induced and -dependent hamster kidney tumours. *Carcinogenesis*, **9**, 925–929

- Lubahn, D.B., McCarty, K.S., Jr & McCarty, K.S., Sr (1985) Electrophoretic characterization of purified bovine, porcine, murine, rat, and human uterine estrogen receptors. *J. biol. Chem.*, **260**, 2515–2526
- Lumb, G., Mitchell, L. & DeLaGlesia, F.A. (1985) Regression of pathologic changes induced by the long-term administration of contraceptive steroids to rodents. *Toxicol. Pathol.*, **13**, 283–295
- Lund, E., Meirik, O., Adami, H.-O., Bergström, R., Christoffersen, T. & Bergsjøss, P. (1989) Oral contraceptive use and premenopausal breast cancer in Sweden and Norway: Possible effects of different patterns of use. *Int. J. Epidemiol.*, **18**, 527–532
- Lundgren, S., Lønning, P.E., Aakvaag, A. & Kvinnsland, S. (1990) Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer. *Cancer Chemother. Pharmacol.*, **27**, 101–105
- Luthy, I.A., Begin, D.J. & Labrie, F. (1988) Androgenic activity of synthetic progestins and spiro-nolactone in androgen-sensitive mouse mammary carcinoma (Shionogi) cells in culture. *J. Steroid Biochem.*, **31**, 845–852
- Lyon, F.A. (1975) The development of adenocarcinoma of the endometrium in young women receiving long-term sequential oral contraception. *Am. J. Obstet. Gynecol.*, **123**, 299–301
- Lyon, F.A. & Frisch, M.J. (1976) Endometrial abnormalities occurring in young women on long-term sequential oral contraceptives. *Obstet. Gynecol.*, **47**, 639–643
- Madden, S. & Back, D.J. (1991) Metabolism of norgestimate by human gastrointestinal mucosa and liver microsomes *in vitro*. *J. Steroid Biochem. mol. Biol.*, **38**, 497–503
- Madden, S., Back, D.J. & Orme, M.L'E. (1990) Metabolism of the contraceptive steroid desogestrel by human liver *in vitro*. *J. Steroid Biochem.*, **35**, 281–288
- Málková, J., Michalová, K., Pribyl, T. & Schreiber, V. (1977) Chromosomal changes in rat pituitary and bone marrow induced by long-term estrogen administration. *Neoplasma*, **24**, 277–284
- Malone, K.E. (1991) *Oral Contraceptives and Breast Cancer. A Review of the Epidemiological Evidence with an Emphasis on Younger Women*, Washington DC, National Academy Press, National Academy of Sciences
- Malone, K.E., Daling, J.R. & Weiss, N.S. (1993) Oral contraceptives in relation to breast cancer. *Epidemiol. Rev.*, **15**, 80–97
- Mamber, S.W., Bryson, V. & Katz, S.E. (1983) The *Escherichia coli* WP2/WP100 rec assay for detection of potential chemical carcinogens. *Mutat. Res.*, **119**, 135–144
- Mant, J.W.F. & Vessey, M.P. (1995) Trends in mortality from primary liver cancer in England and Wales 1975–92: Influence of oral contraceptives. *Br. J. Cancer*, **72**, 800–803
- Markiewicz, L. & Gurbide, E. (1994) Estrogenic and progestagenic activities coexisting in steroidal drugs: Quantitative evaluation by *in vitro* bioassays with human cells. *J. Steroid Biochem. mol. Biol.*, **48**, 89–94
- Markiewicz, L., Hochberg, R.B. & Gurbide, E. (1992) Intrinsic estrogenicity of some progestagenic drugs. *J. Steroid Biochem. mol. Biol.*, **41**, 53–58
- Marr, W., Elder, M.G. & Lim, L. (1980) The effects of oestrogens and progesterone on oestrogen receptors in female rat liver. *Biochem. J.*, **190**, 563–570

- Martelli, A., Mattioli, F., Fazio, S., Andrae, U. & Brambilla, G. (1995) DNA repair synthesis and DNA fragmentation in primary cultures of human and rat hepatocytes exposed to cyproterone acetate. *Carcinogenesis*, **16**, 1265–1269
- Martelli, A., Mattioli, F., Ghia, M., Mereto, E. & Brambilla, G. (1996a) Comparative study of DNA repair induced by cyproterone acetate, chlormadinone acetate, and megestrol acetate in primary cultures of human and rat hepatocytes. *Carcinogenesis*, **17**, 1153–1156
- Martelli, A., Campart, G.B., Ghia, M., Allevena, A., Mereto, E. & Brambilla, G. (1996b) Induction of micronuclei and initiation of enzyme-altered foci in the liver of female rats treated with cyproterone acetate, chlormadinone acetate or megestrol acetate. *Carcinogenesis*, **17**, 551–554
- Martinez, M.E., Grodstein, F., Giovannucci, E., Colditz, G.A., Speizer, F.E., Hennekens, C., Rosner, B., Willett, W.C. & Stampfer, M.J. (1997) A prospective study of reproductive factors, oral contraceptive use, and risk of colorectal cancer. *Cancer Epidemiol. Biomarkers Prev.*, **6**, 1–5
- Martínez-Frías, M.-L., Rodríguez-Pinilla, E., Bermejo, E. & Prieto, L. (1998) Prenatal exposure to sex hormones: A case-control study. *Teratology*, **57**, 8–12
- Maudelonde, T., Lavaud, P., Salazar, G., Laffargue, F. & Rochefort, H. (1991) Progestin treatment depresses estrogen receptor but not cathepsin D levels in needle aspirates of benign breast disease. *Breast Cancer Res. Treat.*, **19**, 95–102
- Mayberry, R.M. & Stoddard-Wright, C. (1992) Breast cancer risk factors among black and white women: Similarities and differences. *Am. J. Epidemiol.*, **136**, 1445–1456
- Mayol, X., Perez-Tomas, R., Cullere, X., Romero, A., Estadella, M.D. & Domingo, J. (1991) Cell proliferation and tumour promotion by ethinyl estradiol in rat hepatocarcinogenesis. *Carcinogenesis*, **12**, 1133–1136
- McClamrock, H.D. & Adashi, E.Y. (1993) Pharmacokinetics of desogestrel. *Am. J. Obstet. Gynecol.*, **168**, 1021–1028
- McGuire, J.L., Phillips, A., Hahn, D.W., Tolman, E.L., Flor, S. & Kafrissen, M.E. (1990) Pharmacologic and pharmacokinetic characteristics of norgestimate and its metabolites. *Am. J. Obstet. Gynecol.*, **163**, 2127–2131
- McLaughlin, L. (1982) *The Pill, John Rock and the Church*, Toronto, Little, Brown & Co., pp. 138–145
- McPherson, K., Vessey, M.P., Neil, A., Doll, R., Jones, L. & Roberts, M. (1987) Early oral contraceptive use and breast cancer: Results of another case-control study. *Br. J. Cancer*, **56**, 653–660
- McTiernan, A.M., Weiss, N.S. & Daling, J.R. (1984) Incidence of thyroid cancer in women in relation to reproductive and hormonal factors. *Am. J. Epidemiol.*, **120**, 423–435
- Meirik, O., Lund, E., Adami, H.-O., Bergström, R., Christoffersen, T. & Bergsjö, P. (1986) Oral contraceptive use and breast cancer in young women. A joint national case-control study in Sweden and Norway. *Lancet*, **ii**, 650–654
- Meirik, O., Farley, T.M.M., Lund, E., Adami, H.-O., Christoffersen, T. & Bergsjö, P. (1989) Breast cancer and oral contraceptives: Patterns of risk among parous and nulliparous women—further analysis of the Swedish-Norwegian material. *Contraception*, **39**, 471–475

- Menegazzi, M., Carcereri-De Prati, A., Suzuki, H., Shinozuka, H., Pibiri, M., Piga, R., Columbano, A. & Ledda-Columbano, G.M. (1997) Liver cell proliferation induced by nafenopin and cyproterone acetate is not associated with increases in activation of transcription factors NF- κ B and AP-1 or with expression of tumor necrosis factor α . *Hepatology*, **25**, 585–592
- Meriggiola, M.C., Bremner, W.J., Paulsen, C.A., Valdiserri, A., Incorvaia, L., Motta, R., Pavani, A., Capelli, M. & Flamigni, C. (1996) A combined regimen of cyproterone acetate and testosterone enanthate as a potentially highly effective male contraceptive. *J. clin. Endocrinol. Metab.*, **81**, 3018–3023
- Miller, D.R., Rosenberg, L., Kaufman, D.W., Schottenfeld, D., Stolley, P.D. & Shapiro, S. (1986) Breast cancer risk in relation to early oral contraceptive use. *Obstet. Gynecol.*, **68**, 863–868
- Miller, D.R., Rosenberg, L., Kaufman, D.W., Stolley, P., Warshauer, M.E. & Shapiro, S. (1989) Breast cancer before age 45 and oral contraceptive use: New findings. *Am. J. Epidemiol.*, **129**, 269–280
- Mills, P.K., Beeson, L., Phillips, R.L. & Fraser, G.E. (1989) Prospective study of exogenous hormone use and breast cancer in Seventh-day Adventists. *Cancer*, **64**, 591–597
- Misdorp, W. (1991) Progestagens and mammary tumors in dogs and cats. *Acta endocrinol.*, **125**, 27–31
- Mitsumori, K., Furukawa, F., Sato, M., Yoshimura, H., Imazawa, T., Nishikawa, A. & Takahashi, M. (1994) Promoting effects of ethinyl estradiol on development of renal proliferative lesions induced by *N*-nitrosobis(2-oxopropyl)amine in female Syrian golden hamsters. *Cancer Res. clin. Oncol.*, **120**, 131–136
- Molina, R., Thomas, D.B., Dabancens, A., Lopez, J., Ray, R.M., Martinez, L. & Salas, O. (1988) Oral contraceptives and cervical carcinoma in situ in Chile. *Cancer Res.*, **48**, 1011–1015
- Moltz, L., Römmler, A., Post, K., Schwartz, U. & Hammerstein, J. (1980) Medium dose cyproterone acetate (CPA): Effects on hormone secretion and on spermatogenesis in men. *Contraception*, **21**, 393–413
- Morabia, A., Szklo, M., Stewart, W., Schuman, L. & Thomas, D.B. (1993) Consistent lack of association between breast cancer and oral contraceptives using either hospital or neighborhood controls. *Prev. Med.*, **22**, 178–186
- Mori, T., Cui, L., Satoru, K., Takahashi, S., Imaida, K., Iwasaki, S., Ito, N. & Shirai, T. (1996) Direct effects of testosterone, dihydrotestosterone and estrogen on 3,2'-dimethyl-4-aminobiphenol-induced prostate carcinogenesis in castrated F344 rats. *Jpn. J. Cancer Res.*, **7**, 570–574
- Moser, G.J., Wolf, D.C., Harden, R., Standeven, A.M., Mills, J., Jirtle, R.L. & Goldsworthy, T.L. (1996) Cell proliferation and regulation of negative growth factors in mouse liver foci. *Carcinogenesis*, **17**, 1835–1840
- Muechler, E.K. & Kohler, D. (1980) Properties of the estrogen receptor in the human oviduct and its interaction with ethinylestradiol and mestranol *in vitro*. *J. clin. Endocrinol. Metab.*, **51**, 962–967
- Muñoz, N., Bosch, F.X., de Sanjosé, S., Vergara, A., del Moral, A., Muñoz, M.T., Tafur, L., Gili, M., Izarzugaza, I., Viladiu, P., Navarro, C., de Ruiz, P.A., Aristizabal, N., Santamaria, M., Orfila, J., Daniel, R.W., Guerrero, E. & Shah, K.V. (1993) Risk factors for cervical intraepithelial neoplasia grade III/carcinoma in situ in Spain and Colombia. *Cancer Epidemiol. Biomarkers Prev.*, **2**, 423–431

- Muñoz, N., Kato, I., Bosch, F.X., Eluf-Neto, J., de Sanjosé, S., Ascunce, N., Gili, M., Izarzugaza, I., Viladiu, P., Tormo, M.-J., Moreo, P., Gonzalez, L.C., Tafur, L., Walboomers, J.M.M. & Shah, K.V. (1996) Risk factors for HPV DNA detection in middle-aged women. *Sex. transm. Dis.*, **23**, 504–510
- Narod, S.A., Risch, H., Moslehi, R., Dorum, A., Neuhausen, S., Olsson, H., Provencher, D., Radice, P., Evans, G., Bishop, S., Brunet, J.S. & Ponder, B.A. (1998) Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. *New Engl. J. Med.*, **339**, 424–428
- Negri, E., La Vecchia, C., Parazzini, F., Savoldelli, R., Gentile, A., D'Avanzo, B., Gramenzi, A. & Franceschi, S. (1989) Reproductive and menstrual factors and risk of colorectal cancer. *Cancer Res.*, **49**, 7158–7161
- Negrini, B.P., Schiffman, M.H., Kurman, R.J., Barnes, W., Lannom, L., Malley, K., Brinton, L.A., Delgado, G., Jones, S., Tchabo, J.-G. & Lancaster, W.D. (1990) Oral contraceptive use, human papillomavirus infection, and risk of early cytological abnormalities of the cervix. *Cancer Res.*, **50**, 4670–4675
- Neuberger, J., Forman, D., Doll, R. & Williams, R. (1986) Oral contraceptives and hepatocellular carcinoma. *Br. med. J.*, **292**, 1355–1357
- Neumann, F., Elger, W. & Kramer, M. (1966) Development of a vagina in male rats by inhibiting androgen receptors through an antiandrogen during the critical phase of organogenesis. *Endocrinology*, **78**, 628–632
- Neumann, I., Thierau, D., Andrae, U., Greim, H. & Schwartz, L.R. (1992) Cyproterone acetate induces DNA damage in cultured rat hepatocytes and preferentially stimulates DNA synthesis in γ -glutamyltranspeptidase-positive cells. *Carcinogenesis*, **13**, 373–378
- Newcomb, P.A., Longnecker, M.P., Storer, B.E., Mittendorf, R., Baron, J., Clapp, R.W., Trentham-Dietz, A. & Willett, W.C. (1996) Recent oral contraceptive use and risk of breast cancer (United States). *Cancer Causes Control*, **7**, 525–532
- New Zealand Contraception and Health Study Group (1994) Risk of cervical dysplasia in users of oral contraceptives, intrauterine devices or depot-medroxyprogesterone acetate. *Contraception*, **50**, 431–441
- Ngelangel, C., Muñoz, N., Bosch, F.X., Limson, G.M., Festin, M.R., Deacon, J., Jacobs, M.V., Santamaria, M., Meijer, C.J.L.M. & Walboomers, J.M.M. (1998) Causes of cervical cancer in the Philippines: A case-control study. *J. natl Cancer Inst.*, **90**, 43–49
- Ni, N. & Yager, J.D. (1994a) Comitogenic effects of estrogens on DNA synthesis induced by various growth factors in cultured female rat hepatocytes. *Hepatology*, **19**, 183–192
- Ni, N. & Yager, J.D. (1994b) The co-mitogenic effects of various estrogens for TGF- α -induced DNA synthesis in cultured female rat hepatocytes. *Cancer Lett.*, **84**, 133–140
- Nielsen, S.T., Conaty, J.M. & DiPasquale, G. (1987) Progesterone receptor of adult rabbit lung. *Pharmacology*, **35**, 217–226
- Nilsson, B. & von Schoultz, B. (1989) Binding of levonorgestrel, norethisterone and desogestrel to human sex hormone binding globulin and influence on free testosterone levels. *Gynecol. obstet. Invest.*, **27**, 151–154

- Nutter, L.M., Wu, Y., Ngo, E.O., Sierra, E.E., Gutierrez, P.L. & Abul-Hajj, Y.J. (1994) An o-quinone form of estrogen produces free radicals in human breast cancer cells: Correlation with DNA damage. *Chem. Res. Toxicol.*, **7**, 23–28
- Oberhammer, F., Nagy, P., Tiefenbacher, R., Fröschl, G., Bouzahzah, B., Thorgeirsson, S.S. & Carr, B. (1996) The antiandrogen cyproterone acetate induces synthesis of transforming growth factor β 1 in the parenchymal cells of the liver accompanied by an enhanced sensitivity to undergo apoptosis and necrosis without inflammation. *Hepatology*, **23**, 329–337
- Ochs, H., Düsterberg, B., Günzel, P. & Schulte-Hermann, R. (1986) Effect of tumor promoting contraceptive steroids on growth and drug metabolizing enzymes in rat liver. *Cancer Res.*, **46**, 1224–1232
- Odlind, V., Weiner, E., Victor, A. & Johansson, E.D.B. (1980) Effects on sex hormone binding globulin of different oral contraceptives containing norethisterone and lynestrenol. *Br. J. Obstet. Gynaecol.*, **87**, 416–421
- Ogawa, T., Higashi, S., Kawarada, Y. & Mizumoto, R. (1995) Role of reactive oxygen in synthetic estrogen induction of hepatocellular carcinomas in rats and preventive effect of vitamins. *Carcinogenesis*, **16**, 831–836
- Olsson, H. (1989) Oral contraceptives and breast cancer. A review. *Acta oncol.*, **6**, 849–863
- Olsson, H., Möller, T.R. & Ranstam, J. (1989) Early oral contraceptive use and breast cancer among premenopausal women: Final report from a study in southern Sweden. *J. natl Cancer Inst.*, **81**, 1000–1004
- Olsson, H., Borg, A., Fermö, M., Möller, T.R. & Ranstam, J. (1991a) Early oral contraceptive use and premenopausal breast cancer—a review of studies performed in southern Sweden. *Cancer Detect. Prev.*, **15**, 265–271
- Olsson, H., Ranstam, J., Baldetorp, B., Ewers, S.-B., Fernö, M., Killander, D. & Sigurdsson, H. (1991b) Proliferation and DNA ploidy in malignant breast tumours in relation to early oral contraceptive use and early abortions. *Cancer*, **67**, 1285–1290
- Olsson, H., Borg, A., Fernö, M., Ranstam, J. & Sigurdsson, H. (1991c) Her-2/neu and INT2 proto-oncogene amplification in malignant breast tumours in relation to reproductive factors and exposure to exogenous hormones. *J. natl Cancer Inst.*, **83**, 1483–1487
- Olsson, H., Jernström, H., Alm, P., Kreipe, H., Ingvar, C., Jönsson, P.-E. & Rydén, S. (1996) Proliferation of the breast epithelium in relation to menstrual cycle phase, hormonal use and reproductive factors. *Breast Cancer Res. Treat.*, **40**, 187–196
- Orme, M.L'E., Back, D.J. & Breckenridge, A.M. (1983) Clinical pharmacokinetics of oral contraceptive steroids. *Clin. Pharmacokin.*, **8**, 95–136
- Ory, H., Cole, P., MacMahon, B. & Hoover, R. (1976) Oral contraceptives and reduced risk of benign breast diseases. *New Engl. J. Med.*, **294**, 419–422
- Østerlind, A., Tucker, M.A., Stone, B.J. & Jensen, O.M. (1988) The Danish case-control study of cutaneous malignant melanoma. III. Hormonal and reproductive factors in women. *Int. J. Cancer*, **42**, 821–824
- Paffenbarger, R.S., Jr, Fasal, E., Simmons, M.E. & Kampert, J.B. (1977) Cancer risk as related to use of oral contraceptives during fertile years. *Cancer*, **39**, 1887–1891

- Palmer, J.R., Rosenberg, L., Kaufman, D.W., Warshauer, M.E., Stolley, P. & Shapiro, S. (1989) Oral contraceptive use and liver cancer. *Am. J. Epidemiol.*, **130**, 878–882
- Palmer, J.R., Rosenberg, L., Strom, B.L., Harlap, S., Zauber, A.G., Warshauer, E.M. & Shapiro, S. (1992) Oral contraceptive use and risk of cutaneous malignant melanoma. *Cancer Causes Control*, **3**, 547–554
- Palmer, J.R., Rosenberg, L., Rao, R.S., Strom, B.L., Warshauer, M.E., Harlap, S., Zauber, A. & Shapiro, S. (1995) Oral contraceptive use and breast cancer risk among African-American women. *Cancer Causes Control*, **6**, 321–331
- Panda, J.N. & Jindal, S.K. (1982) Effect of chronic use of cyproterone acetate on the epididymis of goat. *Andrologia*, **14**, 397–402
- Parádi, E. (1981) Mutagenicity of some contraceptive drugs in *Drosophila melanogaster*. *Mutat. Res.*, **88**, 175–178
- Parazzini, F., La Vecchia, C., Negri, E., Fasoli, M. & Cecchetti, G. (1988) Risk factors for adenocarcinoma of the cervix: A case-control study. *Br. J. Cancer*, **57**, 201–204
- Parazzini, F., La Vecchia, C., Franceschi, S., Negri, E. & Cecchetti, G. (1989) Risk factors for endometrioid, mucinous and serous benign ovarian cysts. *Int. J. Cancer*, **18**, 108–112
- Parazzini, F., La Vecchia, C., Negri, E. & Maggi, R. (1990) Oral contraceptive use and invasive cervical cancer. *Int. J. Epidemiol.*, **19**, 259–263
- Parazzini, F., La Vecchia, C., Negri, E., Bocciolone, L., Fedele, L. & Franceschi, S. (1991a) Oral contraceptives use and the risk of ovarian cancer: An Italian case-control study. *Eur. J. Cancer*, **27**, 594–598
- Parazzini, F., Restelli, C., La Vecchia, C., Negri, E., Chiari, S., Maggi, R. & Mangioni, C. (1991b) Risk factors for epithelial ovarian tumours of borderline malignancy. *Int. J. Epidemiol.*, **20**, 871–877
- Parazzini, F., Franceschi, S., La Vecchia, C. & Fasoli, M. (1991c) The epidemiology of ovarian cancer. *Gynecol. Oncol.*, **43**, 9–23
- Parazzini, F., La Vecchia, C., Negri, E., Fedele, L., Franceschi, S. & Gallotta, L. (1992) Risk factors for cervical intraepithelial neoplasia. *Cancer*, **69**, 2276–2282
- Parazzini, F., La Vecchia, C., Negri, E., Moroni, S. & Villa, A. (1995) Risk factors for benign ovarian teratomas. *Br. J. Cancer*, **71**, 644–646
- Pardthaisong, T., Gray, R.H., McDaniel, E.B. & Chandacham, A. (1988) Steroid contraceptive use and pregnancy outcome. *Teratology*, **38**, 51–58
- Parkin, D.M., Srivatanakul, P., Khlai, M., Chenvidhya, D., Chotiwan, P., Insiripong, S., L'Abbé, K.A. & Wild, C.P. (1991) Liver cancer in Thailand. I. A case-control study of cholangiocarcinoma. *Int. J. Cancer*, **48**, 323–328
- Parzefall, W., Monschau, P. & Schulte-Hermann, R. (1989) Induction by cyproterone acetate of DNA synthesis and mitosis in primary cultures of adult rat hepatocytes in serum free medium. *Arch. Toxicol.*, **63**, 456–461
- Parzefall, W., Erber, E., Sedivy, R. & Schulte-Hermann, R. (1991) Testing for induction of DNA synthesis in human hepatocyte primary cultures by rat liver tumor promoters. *Cancer Res.*, **51**, 1143–1147

- Pasapera, A.M., Cerbón, M.A., Castro, I., Gutiérrez, R., Camacho-Arroyo, I., García, G.A. & Pérez-Palacios, G. (1995) Norethisterone metabolites modulate the uteroglobin and progesterone receptor gene expression in prepubertal rabbits. *Biol. Reprod.*, **52**, 426–432
- Pater, A., Bayatpour, M. & Pater, M.M. (1990) Oncogenic transformation by human papilloma virus type 16 deoxyribonucleic acid in the presence of progesterone or progestins from oral contraceptives. *Am. J. Obstet. Gynecol.*, **162**, 1099–1103
- Paul, C., Skegg, D.C.G., Spears, G.F.S. & Kaldor, J.M. (1986) Oral contraceptives and breast cancer: A national study. *Br. med. J.*, **293**, 723–726
- Paul, C., Skegg, D.C.G. & Spears, G.F.S. (1990) Oral contraceptives and risk of breast cancer. *Int. J. Cancer*, **46**, 366–373
- Paul, C., Skegg, D.C.G. & Spears, G.F.S. (1995) Oral contraceptive use and risk of breast cancer in older women (New Zealand). *Cancer Causes Control*, **6**, 485–491
- Peek, M.J., Markham, R. & Fraser, I.S. (1995) The effects of natural and synthetic sex steroids on human decidual endothelial cell proliferation. *Hum. Reprod.*, **10**, 2238–2243
- Peritz, E., Ramcharan, S., Frank, J., Brown, W.L., Huang, S. & Ray, R. (1977) The incidence of cervical cancer and duration of oral contraceptive use. *Am. J. Epidemiol.*, **106**, 462–469
- Persson, E., Einhorn, N. & Pettersson, F. (1987) A case-control study of oral contraceptive use in women with adenocarcinoma of the uterine cervix. *Eur. J. Obstet. Gynecol. reprod. Biol.*, **26**, 85–90
- Persson, I., Schmidt, M., Adami, H.O., Bergstrom, R., Pettersson, B. & Sparen, P. (1990) Trends in endometrial cancer incidence and mortality in Sweden, 1960–84. *Cancer Causes Control*, **1**, 201–208
- Peter, H., Jung, R., Bolt, H.M. & Oesch, F. (1981) Norethisterone-4 β ,5-oxide and laevonorgestrel-4 β ,5-oxide: Formation in rat liver microsomal incubations and interference with microsomal epoxide hydrolase and cytoplasmic glutathione S-transferase. *J. Steroid Biochem.*, **14**, 83–90
- Peters, R.K., Chao, A., Mack, T.M., Thomas, D., Bernstein, L. & Henderson, B.E. (1986a) Increased frequency of adenocarcinoma of the uterine cervix in young women in Los Angeles County. *J. natl Cancer Inst.*, **76**, 423–428
- Peters, R.K., Thomas, D., Hagan, D.G., Mack, T.M. & Henderson, B.E. (1986b) Risk factors for invasive cervical cancer among Latinas and non-Latinas in Los Angeles County. *J. natl Cancer Inst.*, **77**, 1063–1077
- Peters, R.K., Pike, M.C., Chang, W.W.L. & Mack, T.M. (1990) Reproductive factors and colon cancers. *Br. J. Cancer*, **61**, 741–748
- Pettersson, B., Adami, H.O., Bergstrom, R. & Johansson, E.D. (1986) Menstruation span—A time-limited risk factor for endometrial carcinoma. *Acta obstet. gynecol. scand.*, **65**, 247–255
- Phai, N.V., Knodel, J., Cam, M.V. & Xuyen, H. (1996) Fertility and family planning in Vietnam: Evidence from the 1994 inter-censal demographic survey. *Stud. Fam. Plann.*, **27**, 1–17
- Phillips, A., Hahn, D.W., Klimek, S. & McGuire, J.L. (1987) A comparison of the potencies and activities of progestogens used in contraceptives. *Contraception*, **36**, 181–192
- Phillips, A., Demarest, K., Hahn, D.W., Wong, F. & McGuire, J.L. (1990) Progestational and androgenic receptor binding affinities and *in vivo* activities of norgestimate and other progestins. *Contraception*, **41**, 399–410

- Phillips, A., Hahn, D.W. & McGuire, J.L. (1992) Preclinical evaluation of norgestimate, a progestin with minimal androgenic activity. *Am. J. Obstet. Gynecol.*, **167**, 1191–1196
- Pike, M.C., Henderson, B.E., Casagrande, J.T., Rosario, I. & Gray, G.E. (1981) Oral contraceptive use and early abortion as risk factors for breast cancer in young women. *Br. J. Cancer*, **43**, 72–76
- Pike, M.C., Henderson, B.E., Krailo, M.D., Duke, A. & Roy, S. (1983) Breast cancer in young women and use of oral contraceptives: Possible modifying effect of formulations and age at use. *Lancet*, **ii**, 926–929
- Pinto, M.R. (1986) Possible effects of hormonal contraceptives on human mitotic chromosomes. *Mutat. Res.*, **169**, 149–157
- Piper, J.M. & Kennedy, D.L. (1987) Oral contraceptives in the United States: Trends in content and potency. *Int. J. Epidemiol.*, **16**, 215–221
- Plante, M., Lapointe, S. & Labrie, F. (1988) Stimulatory effect of synthetic progestins currently used for the treatment of prostate cancer on growth of the androgen-sensitive Shionogi tumor in mice. *J. Steroid Biochem.*, **31**, 61–64
- Polednak, A.P. (1985) Exogenous female sex hormones and birth defects. *Public Health Rev.*, **13**, 89–114
- Pollow, K., Juchem, M., Grill, H.J., Elger, W., Beier, S., Schmidt-Gollwitzer, K. & Manz, B. (1990) Lack of binding of gestodene to estrogen receptor in human breast cancer tissue. *Eur. J. Cancer*, **26**, 608–610
- Polychronopoulou, A., Tzonou, A., Hsieh, C., Kaprinis, G., Rebelakos, A., Toupadaki, N. & Trichopoulos, D. (1993) Reproductive variables, tobacco, ethanol, coffee and somatometry as risk factors for ovarian cancer. *Int. J. Cancer*, **55**, 402–407
- Popov, A.A., Visser, A.P. & Ketting, E. (1993) Contraceptive knowledge, attitudes and practice in Russia during the 1980s. *Stud. Family Planning*, **24**, 227–235
- Population Council (1994) Syria 1993: Results from the PAPCHILD Survey. *Stud. Fam. Plann.*, **25**, 248–252
- Population Council (1995) Sudan 1992/93: Results from the PAPCHILD Health Survey. *Stud. Fam. Plann.*, **26**, 116–120
- Population Council (1996a) Bolivia 1994: Results from the Demographic and Health Survey. *Stud. Fam. Plann.*, **27**, 172–176
- Population Council (1996b) Morocco 1995: Results from the Demographic and Health Survey. *Stud. Fam. Plann.*, **27**, 344–348
- Population Council (1997a) Uganda 1995: Results from the Demographic and Health Survey. *Stud. Fam. Plann.*, **28**, 156–160
- Population Council (1997b) Egypt 1995: Results from the Demographic and Health Survey. *Stud. Fam. Plann.*, **28**, 251–255
- Population Council (1997c) Guatemala 1995: Results from the Demographic and Health Survey. *Stud. Fam. Plann.*, **28**, 151–155
- Population Council (1997d) Kazakhstan 1995: Results from the Demographic and Health Survey. *Stud. Fam. Plann.*, **28**, 256–260
- Population Council (1997e) Eritrea 1995: Results from the Demographic and Health Survey. *Stud. Fam. Plann.*, **28**, 336–340

- Population Council (1997f) Mali 1995–96: Results from the Demographic and Health Survey. *Stud. Fam. Plann.*, **28**, 341–345
- Population Council (1998a) Benin 1996: Results from the Demographic and Health Survey. *Stud. Fam. Plann.*, **29**, 83–87
- Population Council (1998b) Brazil 1996: Results from the Demographic and Health Survey. *Stud. Fam. Plann.*, **29**, 88–92
- Potter, J.D. & McMichael, A.J. (1983) Large bowel cancer in women in relation to reproductive and hormonal factors: A case–control study. *J. natl Cancer Inst.*, **71**, 703–709
- Potter, J.D., Bostick, R.M., Grandits, G.A., Fosdick, L., Elmer, P., Wood, J., Grambsch, P. & Louis, T.A. (1996) Hormone replacement therapy is associated with lower risk of adenomatous polyps of the large bowel: The Minnesota Cancer Prevention Research Unit Case–Control Study. *Cancer Epidemiol. Biomarkers Prev.*, **5**, 779–784
- Poulin, R., Baker, D., Poirier, D. & Labrie, F. (1990) Multiple actions of synthetic ‘progestins’ on the growth of ZR-75-1 human breast cancer cells: An *in vitro* model for the simultaneous assay of androgen, progestin, estrogen, and glucocorticoid agonistic and antagonistic activities of steroids. *Breast Cancer Res. Treat.*, **17**, 197–210
- Powell-Jones, W., Thompson, C., Nayfeh, S.N. & Lucier, G.W. (1980) Sex differences in estrogen binding by cytosolic and nuclear components of rat liver. *J. Steroid Biochem.*, **13**, 219–229
- Poyet, P. & Labrie, F. (1985) Comparison of the antiandrogenic/androgenic activities of flutamide, cyproterone acetate and megestrol acetate. *Mol. cell. Endocrinol.*, **42**, 283–288
- Pradat, P. (1992) A case–control study of major congenital heart defects in Sweden—1981–1986. *Eur. J. Epidemiol.*, **8**, 789–796
- Prahalada, S. & Hendrickx, A.G. (1983) Embryotoxicity of Norlestrin, a combined synthetic oral contraceptive, in rhesus macaques (*Macaca mulatta*). *Teratology*, **27**, 215–222
- Prentice, R.L. & Thomas, D.B. (1987) On the epidemiology of oral contraceptives and breast disease. *Adv. Cancer Res.*, **49**, 284–401
- Preston-Martin, S., Bernstein, L., Pike, M.C., Maldonado, A.A. & Henderson, B.E. (1987) Thyroid cancer among young women related to prior thyroid disease and pregnancy history. *Br. J. Cancer*, **55**, 191–195
- Preston-Martin, S., Jin, F., Duda, M.J. & Mack, W.J. (1993) A case–control study of thyroid cancer in women under age 55 in Shanghai (People’s Republic of China). *Cancer Causes Control*, **4**, 431–440
- Primic- akelj, M., Evstifeeva, T., Ravnihar, B. & Boyle, P. (1995) Breast cancer risk and oral contraceptive use in Slovenia women aged 25 to 54. *Int. J. Cancer*, **62**, 414–420
- Prost-Avallet, O., Oursin, J. & Adessi, G.L. (1991) *In vitro* effect of synthetic progestogens on estrone sulfatase activity in human breast carcinoma. *J. Steroid Biochem. mol. Biol.*, **39**, 967–973
- Purdie, D., Green, A., Bain, C., Siskind, V., Ward, B., Hacker, N., Quinn, M., Wright, G., Russell, P. & Susil, B. for the Survey of Women’s Health Group (1995) Reproductive and other factors and risk of epithelial ovarian cancer: An Australian case–control study. *Int. J. Cancer*, **62**, 678–684
- Raman-Wilms, L., Tseng, A.L., Wighardt, S., Einarson, T.R. & Koren, G. (1995) Fetal genital effects of first-trimester sex hormone exposure: A meta-analysis. *Obstet. Gynecol.*, **85**, 141–149

- Ramcharan, S., Pellegrin, F.A., Ray, R. & Hsu, J.P. (1981a) *The Walnut Creek Contraceptive Study. A Prospective Study of the Side Effects of Oral Contraceptives* (NIH Publ No. 81-564), Vol. III, Bethesda, MD, National Institutes of Health
- Ramcharan, S., Pellegrin, F.A., Ray, R. & Hsu, J.-P. (1981b) *A Prospective Study of the Side Effects of Oral Contraceptives, Vol. III, An Interim Report. A Comparison of Disease Occurrence Leading to Hospitalization or Death in Users and Nonusers of Oral Contraceptives* (NIH Publication No. 81-564), Bethesda, MD, National Institutes of Health
- Ranstam, J. & Olsson, H. (1993) Oral contraceptive use among young women in southern Sweden. *J. Epidemiol. Community Health*, **47**, 32–35
- Rao, T.K., Allen, B.E., Cox, J.T. & Epler, J.L. (1983) Enhancement of mutagenic activity in *Salmonella* by contraceptive steroids. *Toxicol. appl. Pharmacol.*, **69**, 48–54
- Rastogi, R.K., Milone, M. & Chieffi, G. (1980) A long-term study of the epididymal and fertility-suppressing effects of cyproterone acetate in the mouse. *Andrologia*, **12**, 476–481
- Ravnihar, B., Siegel, D.G. & Lindtner, J. (1979) An epidemiologic study of breast cancer and benign breast neoplasia in relation to oral contraceptive and estrogen use. *Eur. J. Cancer*, **15**, 395–403
- Ravnihar, B., Zakelj, P., Kosmelj, K. & Stare, J. (1988) A case-control study of breast cancer in relation to oral contraceptive use in Slovenia. *Neoplasma*, **35**, 109–121
- Re, M., Micali, F., Santoro, L., Cuomo, M., Racheli, T., Scapellato, F. & Iannitelli, M. (1979) Histological characteristics of the human testis after long-term treatment with cyproterone acetate. *Arch. Androl.*, **3**, 263–268
- Reboud, S. & Pageaut, G. (1977) Topographical response and epithelial abnormalities of the mouse cervix after parenteral administration of progestational compounds. *Contraception*, **16**, 357–366
- Reel, J.R., Humphrey, R.R., Shih, Y.-H., Windsor, B.L., Sakowski, R., Creger, P.L. & Edgren, R.A. (1979) Competitive progesterone antagonists: Receptor binding and biological activity of testosterone and 19-nortestosterone derivatives. *Fertil. Steril.*, **31**, 552–561
- Risch, H.A., Weiss, N.S., Lyon, J.L., Daling, J.R. & Liff, J.M. (1983) Events of reproductive life and the incidence of epithelial ovarian cancer. *Am. J. Epidemiol.*, **117**, 128–139
- Risch, H.A., Marrett, L.D. & Howe, G.R. (1994) Parity, contraception, infertility, and the risk of epithelial ovarian cancer. *Am. J. Epidemiol.*, **140**, 585–597
- Risch, H.A., Marrett, L.D., Jain, M. & Howe, G.R. (1996) Differences in risk factors for epithelial ovarian cancer by histologic type. Results of a case-control study. *Am. J. Epidemiol.*, **144**, 363–372
- Roberts, R.A., Soames, A.R., Gill, J.H., James, N.H. & Wheeldon, E.B. (1995) Non-genotoxic hepatocarcinogens stimulate DNA synthesis and their withdrawal induces apoptosis, but in different hepatocyte populations. *Carcinogenesis*, **16**, 1693–1698
- Rohan, T.E. & McMichael, A.J. (1988) Oral contraceptive agents and breast cancer: A population-based case-control study. *Med. J. Aust.*, **149**, 520–524
- Röhrborn, G. & Hansmann, I. (1974) Oral contraceptives and chromosome segregation in oocytes of mice. *Mutat. Res.*, **26**, 535–544
- Romieu, I., Willett, W.C., Colditz, G.A., Stampfer, M.J., Rosner, B., Hennekens, C.H. & Speizer, F.E. (1989) Prospective study of oral contraceptive use and risk of breast cancer in women. *J. natl Cancer Inst.*, **81**, 1313–1321

- Romieu, I., Berlin, J.A. & Colditz, G. (1990) Oral contraceptives and breast cancer. Review and meta-analysis. *Cancer*, **66**, 2253–2263
- Ron, E., Kleinerman, R.A., Boice, J.D., Jr, LiVolsi, V.A., Flannery, J.T. & Fraumeni, J.F., Jr (1987) A population-based case-control study of thyroid cancer. *J. natl Cancer Inst.*, **79**, 1–12
- Rooks, J.B., Ory, H.W., Ishak, K.G., Strauss, L.T., Greenspan, J.R., Hill, A.P. & Tyler, C.W. (1979) Epidemiology of hepatocellular adenoma. The role of oral contraceptive use. *J. Am. med. Assoc.*, **242**, 644–648
- Rookus, M.A., van Leeuwen, F.E., for The Netherlands Oral Contraceptives and Breast Cancer Study Group (1994) Oral contraceptives and risk of breast cancer in women aged 20–54 years. *Lancet*, **344**, 844–851
- Rosenberg, L., Shapiro, S., Slone, D., Kaufman, D.W., Helmrich, S.P., Miettinen, P.S., Stolley, P.D., Rosenshein, N.B., Schottenfeld, D. & Engle, R.L., Jr (1982) Epithelial ovarian cancer and combination oral contraceptives. *J. Am. med. Assoc.*, **247**, 3210–3212
- Rosenberg, L., Miller, D.R., Kaufman, D.W., Helmrich, S.P., Stolley, P.D., Shottenfeld, D. & Shapiro, S. (1984) Breast cancer and oral contraceptive use. *Am. J. Epidemiol.*, **119**, 167–176
- Rosenberg, L., Palmer, J.P., Clarke, E.A. & Shapiro, S. (1992) A case-control study of the risk of breast cancer in relation to oral contraceptive use. *Am. J. Epidemiol.*, **136**, 1437–1444
- Rosenberg, L., Palmer, J.R., Zauber, A.G., Warshauer, M.E., Lewis, J.L., Jr, Strom, B.L., Harlap, S. & Shapiro, S. (1994) A case-control study of oral contraceptive use and invasive epithelial ovarian cancer. *Am. J. Epidemiol.*, **139**, 654–661
- Rosenberg, L., Palmer, J.R., Rao, R.S., Zauber, A.G., Strom, B.L., Warshauer, M.E., Harlap, S. & Shapiro, S. (1996) Case-control study of oral contraceptive use and risk of breast cancer. *Am. J. Epidemiol.*, **143**, 25–37
- Rosenblatt, K.A., Thomas, D.B. & the WHO Collaborative Study of Neoplasia and Steroid Contraceptives (1991) Hormonal content of combined oral contraceptives in relation to the reduced risk of endometrial cancer. *Int. J. Cancer*, **49**, 870–874
- Rosenblatt, K.A., Thomas, D.B., Noonan, E.A. & the WHO Collaborative Study of Neoplasia and Steroid Contraceptives (1992) High-dose and low-dose combined oral contraceptives: Protection against epithelial ovarian cancer and the length of the protective effect. *Eur. J. Cancer*, **28A**, 1872–1876
- Rossi, G.L., Bestetti, G.E., Reymond, M.J. & Lemarchand-Béraud, T. (1991) Morphofunctional study of the effects of fetal exposure to cyproterone acetate on the hypothalamo-pituitary-gonadal axis of adult rats. *Exp. Brain Res.*, **83**, 349–356
- Rossing, M.A., Stanford, J.L., Weiss, N.S. & Habel, L.A. (1996) Oral contraceptive use and risk of breast cancer in middle-aged women. *Am. J. Epidemiol.*, **144**, 161–164
- Roy, S. & Chatterjee, S. (1979) The role of antiandrogenic action in cyproterone acetate-induced morphologic and biochemical changes in human semen. *Fertil. Steril.*, **32**, 93–95
- Roy, S.K. & Kar, A.B. (1967) Foetal effect of norethynodrel in rats. *Indian J. exp. Biol.*, **5**, 14–16
- Royal College of General Practitioners (1974) *Oral Contraceptives and Health*, London, Pitman Medical
- Rudali, G. & Guggiari, M. (1974) Studies on the carcinogenic effect of two norgestrels on the mammary gland of the mouse. *C.R. Soc. Biol. Méd.*, **168**, 1190–1194 (in French)

- Ruokonen, A. & Käär, K. (1985) Effects of desogestrel, levonorgestrel and lynestrenol on serum sex hormone binding globulin, cortisol binding globulin, ceruloplasmin and HDL-cholesterol. *Eur. J. Obstet. Gynecol. reprod. Biol.*, **20**, 13–18
- Russell-Briefel, R., Ezzati, T. & Perlman, J. (1985) Prevalence and trends in oral contraceptive use in premenopausal females ages 12–54 years, United States, 1971–80. *Am. J. public Health*, **75**, 1173–1176
- Russo, I.H. & Russo, J. (1991) Progestagens and mammary gland development: Differentiation versus carcinogenesis. *Acta endocrinol.*, **125**, 7–12
- Russo, I.H., Frederick, J. & Russo, J. (1989) Hormone prevention of mammary carcinogenesis by norethynodrel–mestranol. *Breast Cancer Res. Treat.*, **14**, 43–56
- Sannes, E., Lyngset, A. & Nafstad, I. (1983) Teratogenicity and embryotoxicity of orally administered lynestrenol in rabbits. *Arch. Toxicol.*, **52**, 23–33
- dos Santos Silva, I. & Swerdlow, A.J. (1995) Recent trends in incidence of and mortality from breast, ovarian and endometrial cancers in England and Wales and their relation to changing fertility and oral contraceptive use. *Br. J. Cancer*, **72**, 485–492
- Sartwell, P.E., Arthes, F.G. & Tonascia, J.A. (1977) Exogenous hormones, reproductive history, and breast cancer. *J. natl Cancer Inst.*, **59**, 1589–1592
- Sasaki, M., Sugimura, K., Yoshida, M.A. & Abe, S. (1980) Cytogenetic effects of 60 chemicals on cultured human and Chinese hamster cells. *Kromosomo II*, **20**, 574–584
- Saunders, F.J. (1965) Effects on the course of pregnancy of norethynodrel with mestranol (Enovid) administered to rats during early pregnancy. *Endocrinology*, **77**, 873–878
- Saunders, F.J. (1967) Effects of norethynodrel combined with mestranol on the offspring when administered during pregnancy and lactation in rats. *Encocrinology*, **80**, 447–452
- Saunders, F.J. & Elton, R.I. (1967) Effects of ethynodiol diacetate and mestranol in rats and rabbits, on conception, on the outcome of pregnancy and on the offspring. *Toxicol. appl. Pharmacol.*, **11**, 229–244
- Schardein, J.L. (1980) Studies of the components of an oral contraceptive agent in albino rats. II. Progestogenic component and comparison of effects of the components and the combined agent. *J. Toxicol. environ. Health*, **6**, 895–906
- Schauer, G., Blode, H. & Gunzel, P. (1996) Commentary on the publication: Tucker, M.J., Jones, D.V. Human and Exptl. Toxicol., 1996, **15**, 64–66 (Letter to the Editor). *Hum. exp. Toxicol.*, **15**, 597–598
- Schiffman, M.H., Bauer, H.M., Hoover, R.N., Glass, A.G., Cadell, D.M., Rush, B.B., Scott, D.R., Sherman, M.E., Kurman, R.J., Wacholder, S., Stanton, C.K. & Manos, M.M. (1993) Epidemiologic evidence showing that human papillomavirus infection causes most cervical intra-epithelial neoplasia. *J. natl Cancer Inst.*, **85**, 958–964
- Schildkraut, J.M., Hulka, B.S. & Wilkinson, W.E. (1990) Oral contraceptives and breast cancer: A case–control study with hospital and community controls. *Obstet. Gynecol.*, **76**, 395–402
- Schlesselman, J.J. (1995) Net effect of oral contraceptive use on the risk of cancer in women in the United States. *Obstet. Gynecol.*, **85**, 793–801
- Schlesselman, J.J., Stadel, B.V., Murray, P. & Lai, S.-L. (1987) Breast cancer risk in relation to type of estrogen contained in oral contraceptives. *Contraception*, **3**, 595–613

- Schlesselman, J.J., Stadel, B.V., Murray, P. & Lai, S. (1988) Breast cancer in relation to early use of oral contraceptives. No evidence of a latent effect. *J. Am. med. Assoc.*, **259**, 1828–1833
- Schnitzler, R., Foth, J., Degen, G.H. & Metzler, M. (1994) Induction of micronuclei by stilbene-type and steroidal estrogens in Syrian hamster embryo & ovine seminal vesicle cells in vitro. *Mutat. Res.*, **311**, 85–93
- Schoonen, W.G.E.J., Joosten, J.W.H. & Kloosterboer, H.J. (1995a) Effects of two classes of progestagens, pregnane and 19-nortestosterone derivatives, on cell growth of human breast tumor cells: I. MCF-7 cell lines. *J. Steroid Biochem. mol. Biol.*, **55**, 423–437
- Schoonen, W.G.E.J., Joosten, J.W.H. & Kloosterboer, H.J. (1995b) Effects of two classes of progestagens, pregnane and 19-nortestosterone derivatives, on cell growth of human breast tumor cells: II. T47D cell lines. *J. Steroid Biochem. mol. Biol.*, **55**, 439–444
- Schulte-Hermann, R., Hoffman, V., Parzefall, W., Kallenbach, M., Gerhardt, A. & Schuppler, J. (1980a) Adaptive responses of rat liver to the gestagen and anti-androgen cyproterone acetate and other inducers. II. Induction of growth. *Chem.-biol. Interactions*, **31**, 287–300
- Schulte-Hermann, R., Hoffmann, V. & Landgraf, H. (1980b) Adaptive responses of rat liver to the gestagen and anti-androgen cyproterone acetate and other inducers. III. Cytological changes. *Chem.-biol. Interactions*, **31**, 301–311
- Schulte-Hermann, R., Ochs, H., Bursch, W. & Parzefall, W. (1988) Quantitative structure–activity studies on effects of sixteen different steroids on growth and monooxygenases of rat liver. *Cancer Res.*, **48**, 2462–2468
- Schuppler, J. & Gunzel, P. (1979) Liver tumors and steroid hormones in rats and mice. *Arch. Toxicol.*, **Suppl. 2**, 181–195
- Schuppler, J., Gunzel, P. & El Etreby, M.F. (1977) Effect of progestogens on the liver: Comparative evaluation in rodents, dogs and monkeys in long-term toxicity studies. *J. Toxicol. environ. Health*, **3**, 370–371
- Schuppler, J., Dammé, J. & Schulte-Hermann, R. (1983) Assay of some endogenous and synthetic sex steroids for tumor-initiating activity in rat liver using the Solt-Farber system. *Carcinogenesis*, **4**, 239–241
- Schwartz, S.M. & Weiss, N.S. (1986) Increased incidence of adenocarcinoma of the cervix in young women in the United States. *Am. J. Epidemiol.*, **124**, 1045–1047
- Shapiro, S.S., Dyer, R.D. & Colás, A.E. (1978) Synthetic progestins: In vitro potency on human endometrium and specific binding to cytosol receptor. *Am. J. Obstet. Gynecol.*, **132**, 549–554
- Shenfield, G.M. & Griffin, J.M. (1991) Clinical pharmacokinetics of contraceptive steroids. An update. *Clin. Pharmacokinet.*, **20**, 15–37
- Shi, Y.E. & Yager, J.D. (1989) Effects of the liver tumor promoter ethinyl estradiol on epidermal growth factor-induced DNA synthesis and epidermal growth factor receptor levels in cultured rat hepatocytes. *Cancer Res.*, **49**, 3574–3580
- Shimomura, M., Higashi, S. & Mizumoto, R. (1992) ³²P-Postlabelling analysis of DNA adducts in rats during estrogen-induced hepatocarcinogenesis and effect of tamoxifen on DNA adduct level. *Jpn. J. Cancer Res.*, **83**, 438–444

- Shirai, T., Fukushima, S., Ikawa, E., Tagawa, Y. & Ito, N. (1986) Induction of prostate carcinoma in situ at high incidence in F344 rats by a combination of 3,2'-dimethyl-4-aminobiphenyl and ethinyl estradiol. *Cancer Res.*, **46**, 6423–6426
- Shirai, T., Tsuda, H., Ogiso, T., Hirose, M. & Ito, N. (1987) Organ specific modifying potential of ethinyl estradiol on carcinogenesis initiated with different carcinogens. *Carcinogenesis*, **8**, 115–119
- Shirai, T., Nakamura, A., Fukushima, S., Yamamoto, A., Tada, A. & Ito, N. (1990) Different carcinogenic responses in a variety of organs, including the prostate, of five different rat strains given 3,2'-dimethyl-4-aminobiphenyl. *Carcinogenesis*, **11**, 793–797
- Shoupe, D. (1994) New progestins—clinical experiences: Gestodene. *Am. J. Obstet. Gynecol.*, **170**, 1562–1568
- Shu, X.O., Brinton, L.A., Gao, Y.T. & Yuan, J.M. (1989) Population-based case–control study of ovarian cancer in Shanghai. *Cancer Res.*, **49**, 3670–3674
- Shu, X.-O., Brinton, L.A., Zheng, W., Gao, Y.T., Fan, J. & Fraumeni, J.F. (1991) A population-based case–control study of endometrial cancer in Shanghai, China. *Int. J. Cancer*, **49**, 38–43
- Shyama, S.K. & Rahiman, M.A. (1993) Progestin (norethisterone)-induced genetic damage in mouse bone marrow. *Mutat. Res.*, **300**, 215–221
- Shyama, S.K. & Rahiman, M.A. (1996) Genotoxicity of lynoral (ethinylestradiol, an estrogen) in mouse bone marrow cells, in vivo. *Mutat. Res.*, **370**, 175–180
- Shyama, S.K., Rahiman, M.A. & Vijayalaxmi, K.K. (1991) Genotoxic effect of Anovlar 21, an oral contraceptive, on mouse bone marrow. *Mutat. Res.*, **260**, 47–53
- Silverberg, S.G. & Makowski, E.L. (1975) Endometrial carcinoma in young women taking oral contraceptive agents. *Obstet. Gynecol.*, **46**, 503–506
- Silverberg, S.G., Makowski, E.L. & Roche, W.D. (1977) Endometrial carcinoma in women under 40 years of age: Comparison of cases in oral contraceptive users and non-users. *Cancer*, **39**, 592–598
- Simon, W.E., Albrecht, M., Hänsel, M., Dietel, M. & Hölzer, F. (1983) Cell lines derived from human ovarian carcinomas: Growth stimulation by gonadotropic and steroid hormones. *J. natl Cancer Inst.*, **70**, 839–845
- Simpson, J.L. (1985) Relationship between congenital anomalies and contraception. *Adv. Contracept.*, **1**, 3–30
- Simpson, J.L. & Phillips, O.P. (1990) Spermicides, hormonal contraception and congenital malformations. *Adv. Contracept.*, **6**, 141–167
- Sina, J.F., Bean, C.L., Dysart, G.R., Taylor, V.I. & Bradley, M.O. (1983) Evaluation of the alkaline elution/rat hepatocyte assay as a predictor of carcinogenic/mutagenic potential. *Mutat. Res.*, **113**, 357–391
- Singh, O.S. & Carr, D.H. (1970) A study of the effects of certain hormones on human cells in culture. *Can. med. Assoc. J.*, **103**, 349–350
- Sisenwine, S.F., Kimmel, H.B., Liu, A.L. & Ruelius, H.W. (1975a) The presence of DL-, D-, and L-norgestrel and their metabolites in the plasma of women. *Contraception*, **12**, 339–353
- Sisenwine, S.F., Kimmel, H.B., Liu, A.L. & Ruelius, H.W. (1975b) Excretion and stereoselective biotransformations of dl-, d- and l-norgestrel in women. *Drug. Metab. Disposition*, **3**, 180–188

- Spona, J., Huber, J. & Schmidt, J.B. (1986) Inhibition of ovulation with 35 micrograms of ethinyl estradiol and 2 mg cyproterone acetate (Diane 35). *Geburtsh. Frauenheilk.*, **46**, 435–438 (in German)
- Spritzer, P.M., Barbosa-Coutinho, L.M., Poy, M., Orsi, V., Dahlem, N. & Silva, I.S.B. (1995) Effects of norethisterone acetate and tamoxifen on serum prolactin levels, uterine growth and on the presence of uterine immunoreactive prolactin in estradiol-treated ovariectomized rats. *Braz. J. med. biol. Res.*, **28**, 125–130
- Stadel, B.V., Rubin, G.L., Webster, L.A., Schlesselman, J.J., Wingo, P.A. for the Cancer and Steroid Hormone Group (1985) Oral contraceptives and breast cancer in young women. *Lancet*, **ii**, 970–973
- Stadel, B.V., Lai, S., Schlesselman, S.S. & Murray, P. (1988) Oral contraceptives and premenopausal breast cancer in nulliparous women. *Contraception*, **38**, 287–299
- Stanczyk, F.Z. & Roy, S. (1990) Metabolism of levonorgestrel, norethindrone, and structurally related contraceptive steroids. *Contraception*, **42**, 67–96
- Standeven, A.M., Shi, Y.E., Sinclair, J.F., Sinclair, P.R. & Yager, J.D. (1990) Metabolism of the liver tumor promoter ethinyl estradiol by primary cultures of rat hepatocytes. *Toxicol. appl. Pharmacol.*, **102**, 486–496
- Standeven, A.M., Wolf, D.C. & Goldsworthy, T.L. (1994) Interactive effects of unleaded gasoline and estrogen on liver tumor promotion in female B6C3F₁ mice. *Cancer Res.*, **54**, 1198–2104
- Stanford, J.L., Brinton, L.A. & Hoover, R.N. (1989) Oral contraceptives and breast cancer: Results from an expanded case-control study. *Br. J. Cancer*, **60**, 375–378
- Stanford, J.L., Brinton, L.A., Berman, M.L., Mortel, R., Twiggs, L.B., Barrett, R.J., Wilbanks, G.D. & Hoover, R.N. (1993) Oral contraceptives and endometrial cancer: Do other risk factors modify the association? *Int. J. Cancer*, **54**, 243–248
- Stenchever, M.A., Jarvis, J.A. & Kreger, N.K. (1969) Effect of selected estrogens and progestins on human chromosomes in vitro. *Obstet. Gynecol.*, **34**, 249–252
- Stone, S.C. (1995) Desogestrel. *Clin. Obstet. Gynecol.*, **38**, 821–828
- Sutherland, R.L., Hall, R.E., Pang, G.Y.N., Musgrove, E.A. & Clarke, C.L. (1988) Effect of medroxyprogesterone acetate on proliferation and cell cycle kinetics of human mammary carcinoma cells. *Cancer Res.*, **48**, 5084–5091
- Swenberg, J.A. (1981) Utilization of the alkaline elution assay as a short-term test for chemical carcinogens. In: Stich, H.F. & San, R.H.C., eds, *Short-term Tests for Chemical Carcinogens*, New York, Springer-Verlag, pp. 48–58
- Takai, K., Kakizoe, T., Tanaka, Y., Tobisu, K.-I. & Aso, Y. (1991) Trial to induce prostatic cancer in ACI/Seg rats treated with a combination of 3,2'-dimethyl-4-aminobiphenyl and ethinyl estradiol. *Jpn. J. Cancer Res.*, **82**, 286–292
- Takano, K., Yamamura, H., Suzuki, M. & Nishimura, H. (1966) Teratogenic effect of chlormadinone acetate in mice and rabbits. *Proc. Soc. exp. Biol. Med.*, **121**, 455–457
- Talamini, K., La Vecchia, C., Franceschi, S., Colombo, F., Decarli, A., Grattoni, E., Grigoletto, E. & Tognoni, G. (1985) Reproductive and hormone factors and breast cancer in a northern Italian population. *Int. J. Epidemiol.*, **14**, 70–74

- Talamini, R., Franceschi, S., Dal Maso, L., Negri, E., Conti, E., Filiberti, R., Montella, M., Nanni, O. & La Vecchia, C. (1998) The influence of reproductive and hormonal factors on the risk of colon and rectal cancer in women. *Eur. J. Cancer*, **34**, 1070–1076
- Tam, C.C., Wong, Y.C. & Tang, F. (1985) Further regression of seminal vesicles of castrated guinea pig by administration of cyproterone acetate. *Acta anat.*, **124**, 65–73
- Tamaya, T., Nioka, S., Furuta, N., Shimura, T., Takano, N. & Okada, H. (1977) Contribution of functional groups of 19-nor-progestogens to binding to progesterone and estradiol-17 β receptors in rabbit uterus. *Endocrinology*, **100**, 1579–1584
- Tanooka, H. (1977) Development and applications of *Bacillus subtilis* test systems for mutagens, involving DNA-repair deficiency and suppressible auxotrophic mutations. *Mutat. Res.*, **42**, 19–32
- Täuber, U., Kuhnz, W. & Hümpel, M. (1990) Pharmacokinetics of gestodene and ethinyl estradiol after oral administration of a monophasic contraceptive. *Am. J. Obstet. Gynecol.*, **163**, 1414–1420
- Tavani, A., Negri, E., Franceschi, S., Parazzini, F. & La Vecchia, C. (1993a) Oral contraceptives and breast cancer in Northern Italy. Final report from a case-control study. *Br. J. Cancer*, **68**, 568–571
- Tavani, A., Negri, E., Parazzini, F., Franceschi, S. & La Vecchia, C. (1993b) Female hormone utilisation and risk of hepatocellular carcinoma. *Br. J. Cancer*, **67**, 635–637
- Tavassoli, F.A., Casey, H.W. & Norris, H.J. (1988) The morphologic effects of synthetic reproductive steroids on the mammary gland of rhesus monkeys. Mestranol, ethynone, mestranol-ethynone, chloroethynyl norgestrel-mestranol, and anagestone acetate-mestranol combinations. *Am. J. Pathol.*, **131**, 213–234
- Telang, N.T., Suto, A., Wong, G.Y., Osborne, M.P. & Bradlow, H.L. (1992) Induction by estrogen metabolite 16 α -hydroxyestrone of genotoxic damage and aberrant proliferation in mouse mammary epithelial cells. *J. natl Cancer Inst.*, **84**, 634–638
- Thomas, D.B. (1972) Relationship of oral contraceptives to cervical carcinogenesis. *Obstet. Gynecol.*, **40**, 508–518
- Thomas, D.B. (1991a) Oral contraceptives and breast cancer: Review of the epidemiologic literature. *Contraception*, **43**, 597–642
- Thomas, D.B. (1991b) The WHO Collaborative Study of Neoplasia and Steroid Contraceptives: The influence of combined oral contraceptives on risk of neoplasms in developing and developed countries. *Contraception*, **43**, 695–710
- Thomas, D.B. & the WHO Collaborative Study of Neoplasia and Steroid Contraceptives (1991) The influence of combined oral contraceptives on risk of neoplasms in developing and developed countries. *Contraception*, **43**, 695–710
- Thomas, D.B., Noonan, E.A. & the WHO Collaborative Study of Neoplasia and Steroid Contraceptives (1992) Breast cancer and specific types of combined oral contraceptives. *Br. J. Cancer*, **65**, 108–113
- Thomas, E.J., Edridge, W., Weddell, A., McGill, A. & McGarrigle, H.H.G. (1993) The impact of cigarette smoking on the plasma concentrations of gonadotrophins, ovarian steroids and androgens and upon the metabolism of oestrogens in the human female. *Hum. Reprod.*, **8**, 1187–1193

- Thomas, D.B., Noonan, E.A. & the WHO Collaborative Study of Neoplasia and Steroid Contraceptives (1994) Risk of breast cancer in relation to use of combined oral contraceptives near the age of menopause. *Cancer Causes Control*, **2**, 389–394
- Thomas, D.B., Ray, R.M. & WHO Collaborative Study of Neoplasia and Steroid Contraceptives (1996) Oral contraceptives and invasive adenocarcinomas and adenosquamous carcinomas of the uterine cervix. *Am. J. Epidemiol.*, **144**, 281–289
- Thorogood, M. & Villard-Mackintosh, L. (1993) Combined oral contraceptives: Risks and benefits. *Br. med. Bull.*, **49**, 124–139
- Tomasson, H. & Tomasson, K. (1996) Oral contraceptives and risk of breast cancer. A historical prospective case–control study. *Acta obstet. gynaecol. scand.*, **75**, 157–161
- Topham, J.C. (1980) Do induced sperm-head abnormalities in mice specifically identify mammalian mutagens rather than carcinogens? *Mutat. Res.*, **74**, 379–387
- Topinka, J., Andrae, U., Schwartz, L.R. & Wolff, T. (1993) Cyproterone acetate generates DNA adducts in rat liver and in primary rat hepatocyte cultures. *Carcinogenesis*, **14**, 423–427
- Topinka, J., Binkova, B., Zhu, H.K., Andrae, U., Neumann, I., Schwartz, L.R., Werner, S. & Wolff, T. (1995) DNA-damaging activity of the cyproterone acetate analogues chlormadinone acetate and megestrol acetate in rat liver. *Carcinogenesis*, **16**, 1483–1487
- Trapido, E.J. (1983) A prospective cohort study of oral contraceptives and cancer of the endometrium. *Int. J. Epidemiol.*, **12**, 297–300
- Tryggvadóttir, L., Tulinius, H. & Gudmundsdóttir, G.B. (1997) Oral contraceptive use at a young age and the risk of breast cancer: An Icelandic, population-based cohort study of the effect of birth year. *Br. J. Cancer*, **75**, 139–143
- Tsutsui, T., Suzuki, N., Fukuda, S., Sato, M., Maizumi, H., McLacklan, J.A. & Barrett, J.C. (1987) 17 β -Estradiol-induced cell transformation and aneuploidy of Syrian hamster embryo cells in culture. *Carcinogenesis*, **8**, 1715–1719
- Tsutsui, T., Suzuki, N., Maizumi, H. & Barrett, J.C. (1990) Aneuploidy induction in human fibroblasts: Comparison with results in Syrian hamster fibroblasts. *Mutat. Res.*, **240**, 241–249
- Tsutsui, T., Komine, A., Huff, J. & Barrett, J.C. (1995) Effects of testosterone, testosterone propionate, 17 β -trenbolone and progesterone on cell transformation and mutagenesis in Syrian hamster embryo cells. *Carcinogenesis*, **16**, 1329–1333
- Tsutsui, T., Taguchi, S., Tanaka, Y. & Barrett, C. (1997) 17 β -Estradiol, diethylstilbestrol, tamoxifen, toremifene 7 ICI 164,384 induce morphological transformation and aneuploidy in cultured Syrian hamster embryo cells. *Int. J. Cancer*, **70**, 188–193
- Tuchmann-Duplessis, H. & Mercier-Parot, L. (1972) Effect of a contraceptive steroid on offspring. *J. Gynécol. obstét. Biol. Reprod.*, **1**, 141–159 (in French)
- Tucker, M.J. & Jones, D.V. (1996) Effects of cyproterone acetate in C57B1/10J mice. *Hum. exp. Toxicol.*, **15**, 64–66
- Tucker, M.J., Kalinowski, A.E. & Orton, T.C. (1996) Carcinogenicity of cyproterone acetate in the mouse. *Carcinogenesis*, **17**, 1473–1476
- Tzonou, A., Day, N.E., Trichopoulos, D., Walker, A., Saliarakis, M., Papapostolou, M. & Polychronopoulou, A. (1984) The epidemiology of ovarian cancer in Greece: A case–control study. *Eur. J. Cancer clin. Oncol.*, **20**, 1045–1052

- UK National Case-Control Study Group (1989) Oral contraceptive use and breast cancer risk in young women. *Lancet*, **i**, 973–982
- UK National Case-Control Study Group (1990) Oral contraceptive use and breast cancer risk in young women: Subgroup analyses. *Lancet*, **335**, 1507–1509
- Umapathy, E. & Rai, U.C. (1982) Effect of antiandrogens and medroxyprogesterone acetate on testicular morphometry in mice. *Acta morphol. acad. sci. hung.*, **30**, 99–108
- United Nations (1996) *Levels and Trends of Contraceptive Use as Assessed in 1994*, New York, Department for Economic and Social Information and Policy Analysis, Population Division
- United States Census Bureau (1998) Int. Data Base <http://www.census.gov/ipc/www/idbacc.html>
- Ursin, G., Aragaki, C.C., Paganini-Hill, A., Siemiatycki, J., Thompson, W.D. & Haile, R.W. (1992) Oral contraceptives and premenopausal bilateral breast cancer: A case-control study. *Epidemiology*, **3**, 414–419
- Ursin, G., Peters, B.E., Henderson, B.E., d'Ablaing, G., III, Monroe, K.R. & Pike, M.C. (1994) Oral contraceptive use and adenocarcinoma of the cervix. *Lancet*, **344**, 1390–1394
- Ursin, G., Hendersen, B.E., Haile, R.W., Pike, M.C., Zhou, N., Diep, A. & Bernstein, L. (1997) Does oral contraceptive use increase the risk of breast cancer in women with BrCA1/BrCA2 mutations more than in other women? *Cancer Res.*, **57**, 3678–3681
- Vall Mayans, M., Calvet, X., Bruix, J., Bruguera, M., Costa, J., Estève, J., Bosch, F.X., Bru, C. & Rodés, J. (1990) Risk factors for hepatocellular carcinoma in Catalonia, Spain. *Int. J. Cancer*, **46**, 378–381
- Vessey, M.P. & Painter, R. (1995) Endometrial and ovarian cancer and oral contraceptives—Findings in a large cohort study. *Br. J. Cancer*, **71**, 1340–1342
- Vessey, M.P., Doll, R. & Sutton, P.M. (1972) Oral contraceptives and breast neoplasia: A retrospective study. *Br. med. J.*, **iii**, 719–724
- Vessey, M.P., Doll, R. & Jones, K. (1975) Oral contraceptives and breast cancer. *Lancet*, **i**, 941–944
- Vessey, M., Doll, R., Peto, R., Johnson, B. & Wiggins, P. (1976) A long-term follow-up study of women using different methods of contraception—An interim report. *J. biosoc. Sci.*, **8**, 373–427
- Vessey, M.P., McPherson, K., Yeates, D. & Doll, R. (1982) Oral contraceptive use and abortion before first term pregnancy in relation to breast cancer risk. *Br. J. Cancer*, **45**, 327–331
- Vessey, M., Buron, J., Doll, R., McPherson, K. & Yeates, D. (1983) Oral contraceptives and breast cancer: Final report of an epidemiologic study. *Br. J. Cancer*, **47**, 455–462
- Vessey, M.P., McPherson, K., Villard-Mackintosh, L. & Yeates, D. (1989a) Oral contraceptives and breast cancer: Latest findings in a large cohort study. *Br. J. Cancer*, **59**, 613–617
- Vessey, M.P., Villard-Mackintosh, L., McPherson, K. & Yeates, D. (1989b) Mortality among oral contraceptive users: 20 year follow up of women in a cohort study. *Br. med. J.*, **299**, 1487–1491
- Vickers, A.E.M. & Lucier, G.W. (1991) Estrogen receptor, epidermal growth factor receptor and cellular ploidy in elutriated subpopulations of hepatocytes during liver tumor promotion by 17 α -ethinylestradiol in rats. *Carcinogenesis*, **12**, 391–399
- Vickers, A.E.M. & Lucier, G.W. (1996) Estrogen receptor levels and occupancy in hepatic sinusoidal endothelial and Kupffer cells are enhanced by initiation with diethylnitrosamine and promotion with 17 α -ethinylestradiol in rats. *Carcinogenesis*, **17**, 1235–1242

- Vickers, A.E.M., Nelson, K., McCoy, Z. & Lucier, G.W. (1989) Changes in estrogen receptor, DNA ploidy, and estrogen metabolism in rat hepatocytes during a two-stage model for hepatocarcinogenesis using 17 α -ethinylestradiol as the promoting agent. *Cancer Res.*, **49**, 6512–6520
- Villard-Mackintosh, L., Vessey, M.P. & Jones, L. (1989) The effects of oral contraceptives and parity on ovarian cancer trends in women under 55 years of age. *Br. J. Obstet. Gynaecol.*, **96**, 783–788
- Vizcaino, A.P., Moreno, V., Bosch, F.X., Muñoz, N., Barros-Dios, X.M. & Parkin, D.M. (1998) International trends in the incidence of cervical cancer: I. Adenocarcinoma and adenocarcinoma squamous cell carcinomas. *Int. J. Cancer*, **75**, 536–545
- Voigt, L.F., Deng, Q. & Weiss, N.S. (1994) Recency, duration, and progestin content of oral contraceptives in relation to the incidence of endometrial cancer (Washington, USA). *Cancer Causes Control*, **5**, 227–233
- Waetjen, L.E. & Grimes, D.A. (1996) Oral contraceptives and primary liver cancer: Temporal trends in three countries. *Obstet. Gynecol.*, **88**, 945–949
- Walker, A.H., Bernstein, L., Warren, D.W., Warner, N.E., Zheng, X. & Henderson, B.E. (1990) The effect of *in utero* ethinyl oestradiol exposure on the risk of cryptorchid testis and testicular teratoma in mice. *Br. J. Cancer*, **62**, 599–602
- Walnut Creek Contraceptive Drug Study (1981) *A Prospective Study of the Side Effects of Oral Contraceptives*, Vol. 1, *Findings in Oral Contraceptive Users and Nonusers at Entry into the Study* (DHEW Publ. No. (NIH) 74-562), Bethesda, MD, National Institutes of Health
- Wang, C. & Yeung, K.K. (1980) Use of low-dosage cyproterone acetate as a male contraceptive. *Contraception*, **21**, 245–272
- Wanless, I.R. & Medline, A. (1982) Role of estrogens as promoters of hepatic neoplasia. *Lab. Invest.*, **46**, 313–320
- Warriar, N., Pagé, N., Koutsilieris, M. & Govindan, M.V. (1993) Interaction of antiandrogen-androgen receptor complexes with DNA and transcription activation. *J. Steroid Biochem. mol. Biol.*, **46**, 699–711
- Weinstein, A.L., Mahoney, M.C., Nasca, P.C., Leske, M.C. & Varma, A.O. (1991) Breast cancer risk and oral contraceptive use: Results from a large case-control study. *Epidemiology*, **2**, 353–358
- Weiss, N.S. & Sayvetz, T.A. (1980) Incidence of endometrial cancer in relation to the use of oral contraceptives. *New Engl. J. Med.*, **302**, 551–554
- Weiss, N.S., Lyon, J.L., Liff, J.M., Vollmer, W.M. & Daling, J.R. (1981a) Incidence of ovarian cancer in relation to the use of oral contraceptives. *Int. J. Cancer*, **28**, 669–671
- Weiss, N.S., Daling, J.R. & Chow, W.H. (1981b) Incidence of cancer of the large bowel in women in relation to reproductive and hormonal factors. *J. natl Cancer Inst.*, **67**, 57–60
- Werner, S., Topinka, J., Wolff, T. & Schwartz, L.R. (1995) Accumulation and persistence of DNA adducts of the synthetic steroid cyproterone acetate in rat liver. *Carcinogenesis*, **16**, 2369–2372
- Werner, S., Topinka, J., Kunz, S., Beckurts, T., Heidecke, C.-D., Schwartz, L.R. & Wolff, T. (1996) Studies on the formation of hepatic DNA adducts by the antiandrogenic and gestagenic drug, cyproterone acetate. *Adv. exp. Med. Biol.*, **387**, 253–257

- Westerdahl, J., Olsson, H., Måsbäck, A., Ingvar, C. & Jonsson, N. (1996) Risk of malignant melanoma in relation to drug intake, alcohol, smoking and hormonal factors. *Br. J. Cancer*, **73**, 1126–1131
- Westhoff, C., Pike, M. & Vessey, M. (1988) Benign ovarian teratomas: A population-based case-control study. *Br. J. Cancer*, **58**, 93–98
- Wharton, C. & Blackburn, R. (1988) Lower dose pills. *Population Rep.*, **16**, 1–31
- Wheeler, W.J., Cherry, L.M., Downs, T. & Hsu, T.C. (1986) Mitotic inhibition and aneuploidy induction by naturally occurring synthetic estrogens in Chinese hamster cells in vitro. *Mutat. Res.*, **171**, 31–41
- Wheeler, C.M., Parmenter, C.A., Hung, W.C., Becker, T.M., Greer, C.E., Hildesheim, A. & Manos, M.M. (1993) Determinants of genital human papillomavirus infection among cytologically normal women attending the University of New Mexico Student Health Center. *Sex. transm. Dis.*, **20**, 286–289
- White, J.O., Moore, P.A., Marr, W., Elder, M.G. & Lim, L. (1982) Comparative effects of progesterone, norgestrel, norethisterone and tamoxifen on the abnormal uterus of the anovulatory rat. *Biochem. J.*, **208**, 199–204
- White, E., Malone, K.E., Weiss, N.S. & Daling, J.R. (1994) Breast cancer among young US women in relation to oral contraceptive use. *J. natl Cancer Inst.*, **86**, 505–514
- Whittemore, A.S., Harris, R., Itnyre, J. & the Collaborative Ovarian Cancer Group (1992) Characteristics relating to ovarian cancer risk: Collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. *Am. J. Epidemiol.*, **136**, 1184–1203
- WHO (1992) *Oral Contraceptives and Neoplasia. Report of a WHO Scientific Group* (WHO Technical Report Series 817), Geneva, pp. 18–21
- WHO Collaborative Study of Neoplasia and Steroid Contraceptives (1988) Endometrial cancer and combined oral contraceptives. *Int. J. Epidemiol.*, **17**, 263–269
- WHO Collaborative Study of Neoplasia and Steroid Contraceptives (1989a) Epithelial ovarian cancer and combined oral contraceptives. *Int. J. Epidemiol.*, **18**, 538–545
- WHO Collaborative Study of Neoplasia and Steroid Contraceptives (1989b) Combined oral contraceptives and liver cancer. *Int. J. Cancer*, **43**, 254–259
- WHO Collaborative Study of Neoplasia and Steroid Contraceptives (1989c) Combined oral contraceptives and gallbladder cancer. *Int. J. Epidemiol.*, **18**, 309–314
- WHO Collaborative Study of Neoplasia and Steroid Contraceptives (1990) Breast cancer and combined oral contraceptives: Results from multinational study. *Br. J. Cancer*, **61**, 110–119
- WHO Collaborative Study of Neoplasia and Steroid Contraceptives (1993) Invasive squamous cell cervical carcinoma and combined oral contraceptives: Results from a multinational study. *Int. J. Epidemiol.*, **55**, 228–236
- Wilde, M.I. & Balfour, J.A. (1995) Gestodene: A review of its pharmacology, efficacy and tolerability in combined contraceptive preparations. *Drugs*, **50**, 365–395
- Willett, W.C., Bain, C., Hennekens, C.H., Rosner, B. & Speizer, F.E. (1981) Oral contraceptives and risk of ovarian cancer. *Cancer*, **48**, 1684–1687

- Williams, C.L. & Stancel, G.M. (1996) Estrogens and progestins. In: Wonsiewicz, M.J. & McCurdy, P., eds, *Goodman & Gilman's The Pharmacological Basis of Therapeutics*, 9th Ed., New York, McGraw-Hill, pp. 1411–1440
- Williams, G., Anderson, E., Howell, A., Watson, R., Coyne, J., Roberts, S.A. & Potten, C.S. (1991) Oral contraceptive (OCP) use increases proliferation and decreases oestrogen receptor content of epithelial cells in the normal human breast. *Int. J. Cancer*, **48**, 206–210
- Wilson, J.G. & Brent, R.L. (1981) Are female sex hormones teratogenic? *Am. J. Obstet. Gynecol.*, **141**, 567–580
- Wingo, P.A., Lee, N.C., Ory, H.W., Beral, V., Peterson, H.B. & Rhodes, P. (1991) Age-specific differences in relationship between oral contraceptive use and breast cancer. *Obstet. Gynecol.*, **78**, 161–170
- Wingren, G., Hatschek, T. & Axelson, O. (1993) Determinants of papillary cancer of the thyroid. *Am. J. Epidemiol.*, **138**, 482–491
- Worth, A.J. & Boyes, D.A. (1972) A case-control study into the possible effects of birth control pills on pre-clinical carcinoma of the cervix. *J. Obstet. Gynaecol. Br. Commonw.*, **79**, 673–679
- Wu, M.L., Whittemore, A.S., Paffenbarger, R.S., Jr, Sarles, D.L., Kampert, J.B., Grosser, S., Jung, D.L., Ballon, S., Hendrickson, M. & Mohle-Boetani, J. (1988) Personal and environmental characteristics related to epithelial ovarian cancer. I. Reproductive and menstrual events and oral contraceptive use. *Am. J. Epidemiol.*, **128**, 1216–1227
- Wu-Williams, A.H., Lee, M., Whittemore, A.S., Gallagher, R.P., Jiao, D., Zheng, S., Zhou, L., Wang, X., Chen, K., Jung, D., Teh, C.-Z., Ling, C., Xu, J.Y. & Paffenbarger, R.S., Jr (1991) Reproductive factors and colorectal cancer risk among Chinese females. *Cancer Res.*, **51**, 2307–2311
- Yager, J.D., Jr (1983) Oral contraceptive steroids as promoters or complete carcinogens for liver in female Sprague-Dawley rats. *Environ. Health Perspectives*, **50**, 109–112
- Yager, J.D., Jr & Fifield, D.S., Jr (1982) Lack of hepatogenotoxicity of oral contraceptive steroids. *Carcinogenesis*, **3**, 625–628
- Yager, J.D. & Liehr, J.G. (1996) Molecular mechanisms of estrogen carcinogenesis. *Ann. Rev. Pharmacotoxicol.*, **36**, 203–232
- Yager, J.D. & Yager, R. (1980) Oral contraceptive steroids as promoters of hepatocarcinogenesis in female Sprague-Dawley rats. *Cancer Res.*, **40**, 3680–3685
- Yager, J.D., Campbell, H.A., Longnecker, D.S., Roebuck, B.D. & Benoit, M.C. (1984) Enhancement of hepatocarcinogenesis in female rats by ethinyl estradiol and mestranol, but not estradiol. *Cancer Res.*, **44**, 3862–3869
- Yager, J.D., Roebuck, B.D., Paluszcyk, T.L. & Memoli, V.A. (1986) Effects of ethinyl estradiol and tamoxifen on liver DNA turnover and new synthesis and appearance of gamma glutamyl transpeptidase-positive foci in female rats. *Carcinogenesis*, **7**, 2007–2014
- Yager, J.D., Zurlo, J. & Ni, N. (1991) Sex hormones and tumor promotion in liver. *Proc. Soc. exp. Biol. Med.*, **198**, 667–674
- Yager, J.D., Zurlo, J., Sewall, C.H., Lucier, G.E. & He, H. (1994) Growth stimulation followed by growth inhibition in livers of female rats treated with ethinyl estradiol. *Carcinogenesis*, **15**, 2117–2123

- Yamafuji, K., Iiyama, S. & Shinohara, K. (1971) Mode of action of steroid hormones on deoxyribonucleic acid. *Enzymology*, **40**, 259–264
- Yamagiwa, K., Higashi, S. & Mizumoto, R. (1991) Effect of alcohol ingestion on carcinogenesis by synthetic estrogen and progestin in the rat liver. *Jpn. J. Cancer Res.*, **82**, 771–778
- Yamagiwa, K., Mizumoto, R., Higashi, S., Kato, H., Tomida, T., Uehara, S., Tanigawa, K., Tanaka, M. & Ishida, N. (1994) Alcohol ingestion enhances hepatocarcinogenesis induced by synthetic estrogen and progestin in the rat. *Cancer Detect. Prev.*, **18**, 103–114
- Yamamoto, T., Terada, N., Nishizawa, Y. & Petrow, V. (1994) Angiostatic activities of medroxyprogesterone acetate and its analogues. *Int. J. Cancer*, **56**, 393–399
- Yasuda, Y., Kihara, T., Tanimura, T. & Nishimura, H. (1985) Gonadal dysgenesis induced by prenatal exposure to ethinyl estradiol in mice. *Teratology*, **32**, 219–227
- Yasuda, Y., Konishi, H. & Tanimura, T. (1986) Leydig cell hyperplasia in fetal mice treated transplacentally with ethinyl estradiol. *Teratology*, **33**, 281–288
- Yasuda, Y., Ohara, I., Konishi, H. & Tanimura, T. (1988) Long-term effects on male reproductive organs of prenatal exposure to ethinyl estradiol. *Am. J. Obstet. Gynecol.*, **159**, 1246–1250
- Ye, Z., Thomas, D.B., Ray, R.M. & WHO Collaborative Study of Neoplasia and Steroid Contraceptives (1995) Combined oral contraceptives and risk of cervical cancer in situ. *Int. J. Epidemiol.*, **24**, 19–26
- Yen, S., Hsieh, C.-C. & MacMahon, B. (1987) Extrahepatic bile duct cancer and smoking, beverage consumption, past medical history, and oral-contraceptive use. *Cancer*, **59**, 2112–2116
- Yu, M.C., Tong, M.J., Govindarajan, S. & Henderson, B.E. (1991) Nonviral risk factors for hepatocellular carcinoma in a low-risk population, the non-Asians of Los Angeles County, California. *J. natl Cancer Inst.*, **83**, 1820–1826
- Yuan, J.-M., Yu, M.C., Ross, R.K., Gao, Y.-T. & Henderson, B.E. (1988) Risk factors for breast cancer in Chinese women in Shanghai. *Cancer Res.*, **48**, 1949–1953
- Zanetti, R., Franceschi, S., Rosso, S., Bidoli, E. & Colonna, S. (1990) Cutaneous malignant melanoma in females: The role of hormonal and reproductive factors. *Int. J. Epidemiol.*, **19**, 522–526
- Zarghami, N., Grass, L. & Diamandis, E.P. (1997) Steroid hormone regulation of prostate-specific antigen gene expression in breast cancer. *Br. J. Cancer*, **75**, 579–588
- Zaridze, D., Mukeria, A. & Duffy, S.W. (1992) Risk factors for skin melanoma in Moscow. *Int. J. Cancer*, **52**, 159–161
- Zondervan, K.T., Carpenter, L.M., Painter, R. & Vessey, M.P. (1996) Oral contraceptives and cervical cancer—Further findings from the Oxford Family Planning contraceptive study. *Br. J. Cancer*, **73**, 1291–1297